

Extended Effects of a Wearable Sensory Prosthesis on Gait, Balance Function and Falls After 26 Weeks of Use in Persons with Peripheral Neuropathy and High Fall Risk – The walk2Wellness Trial

Lars IE Oddsson^{1,2,3}, Teresa Bisson^{2,4}, Helen S Cohen⁵, Ikechukwu Iloputaife⁶, Laura Jacobs¹, Doris Kung⁵, Lewis A Lipsitz^{6,7,8}, Brad Manor^{6,7,8}, Patricia McCracken⁹, Yvonne Rumsey¹, Diane M Wrisley¹⁰, Sara R Koehler-McNicholas^{2,9}.

¹ RxFunction Inc. MN, USA;

² University of Minnesota, MN, USA;

³ Ben Gurion University of the Negev, Israel;

⁴ M Health Fairview, Minneapolis, MN, USA;

⁵ Baylor College of Medicine, Houston, TX, USA;

⁶ Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Roslindale, MA, USA.

⁷ Division of Gerontology, Beth Israel Deaconess Medical Center, Boston, MA, USA;

⁸ Harvard Medical School, Boston, MA, USA;

⁹ Minneapolis Department of Veterans Affairs Health Care System, Minneapolis, MN, USA;

¹⁰ College of St Mary, Omaha, NE, USA;

Keywords: Peripheral Neuropathy, Falls, Balance, Gait Speed, Neuromodulation, Clinical Trial, Sensory Prosthesis, Non-invasive, Wearable

Abstract

Background: We recently reported that individuals with impaired plantar sensation and high fall risk due to sensory peripheral neuropathy (PN) improved gait and balance function following 10 weeks of use of Walkasins[®], a wearable lower limb sensory prosthesis that provides directional tactile stimuli related to plantar pressure measurements during standing and walking (RxFunction Inc., MN, USA). Here, we report 26-week outcomes and compare pre- and in-study fall rates. We expected improvements in outcomes and reduced fall rates reported after 10 weeks of use to be sustained.

Methods: Participants had clinically diagnosed PN with impaired plantar sensation, high fall risk (Functional Gait Assessment, FGA score <23) and ability to sense tactile stimuli above the ankle at the location of the device. Additional outcomes included 10m Gait Speed, Timed Up&Go (TUG), Four-Stage Balance Test, and self-reported outcomes, including Activities-Specific Balance Confidence scale and Vestibular Disorders Activities of Daily Living Scale. Participants tracked falls using a calendar.

Results: We assessed falls and self-reported outcomes from 44 individuals after 26 weeks of device use; 30 of them conducted in-person testing of clinical outcomes. Overall, improvements in clinical outcomes seen at 10 weeks of use remained sustained at 26 weeks with statistically significant increases compared to baseline seen in FGA scores (from 15.0 to 19.2), self-selected gait speed (from 0.89 m/s to 0.97 m/s), and 4-Stage Balance Test (from 25.6s to 28.4s), indicating a decrease in fall risk. Non-significant improvements were observed in TUG and fast gait speed. Overall, 39 falls were reported; 31 of them did not require medical treatment and four caused severe injury. Participants who reported falls over 6 months prior to the study had a 43% decrease in fall rate during the study as compared to self-report 6-month pre-study (11.8 vs. 6.7 falls/1000 patient days, respectively, $p < 0.004$), similar to the 46% decrease reported after 10 weeks of use.

Conclusion: A wearable sensory prosthesis can improve outcomes of gait and balance function and substantially decreases incidence of falls during long-term use. The sustained long-term benefits in clinical outcomes reported here lessen the likelihood that improvements are placebo effects.

Trial registration: ClinicalTrials.gov (#NCT03538756)

50 1 Introduction

51 Persistent problems with gait and balance function may lead to falls, fractures, and other serious
52 injuries in older adults (Bergen, Stevens et al. 2016, Ganz and Latham 2020, Moreland, Kakara et al.
53 2020). In fact, clinical observations on the problem of falls and fall prevention go back to at least
54 1948 when Sheldon (Sheldon 1948) presented data in *The Lancet* on “Liability to Falls” in older
55 adults, concluding that falling was “a clinical problem which has never received the attention it
56 deserves.” Today, we appreciate that causes of falls are complex and require a multifactorial clinical
57 approach to arrive at a correct diagnosis and to provide specific and relevant therapeutic interventions
58 (Cohen, Miller et al. 2015).

59
60 To address the problem of falls in older adults, various clinical practice guidelines for falls
61 prevention and management have been developed (Montero-Odasso, Kamkar et al. 2021). The
62 Centers for Disease Control and Prevention (CDC), for example, has established “STEADI”
63 (STEADI 2021), an evidence-based initiative to address fall prevention based on a curation of
64 decades of research activities (Stevens and Phelan 2013). At this time, advice provided through the
65 STEADI initiative includes “Talk to your doctor”; “Do Strength and Balance Exercises”; “Have Your
66 Eyes Checked”; and “Make Your Home Safer”(CDC 2021). At a minimum, health care providers
67 should screen their patients for fall risk, including older adults and individuals with
68 neurodegenerative diseases that affect balance function. Simple interventions that should be
69 considered to help reduce the risk for falls include medication management and vitamin D
70 supplements to improve bone, muscle, and nerve health (Bergen, Stevens et al. 2016). Further
71 treatment of gait and balance issues may involve use of canes, walkers, and rehabilitation
72 interventions with balance exercises (Richardson, Sandman et al. 2001, Halvarsson, Franzén et al.
73 2013, Melzer and Oddsson 2013, Ganz and Latham 2020), including Tai-Chi (Li and Manor 2010,
74 Manor, Lough et al. 2014, Quigley, Bulat et al. 2014). Any functional benefits related to fall rates
75 and gait function after long-term use of bilateral ankle foot orthoses appear limited (Wang, Goel et al.
76 2019).

77
78 In addition to other age-related risk factors, sensory peripheral neuropathy (PN), leading to impaired
79 plantar sensation, is an independent risk factor for falls (Richardson and Hurvitz 1995, Koski,
80 Luukinen et al. 1998, Reeves, Orlando et al. 2021), irrespective of whether the underlying cause is
81 due to diabetes (Mustapa, Justine et al. 2016, Vinik, Camacho et al. 2017), chemotherapy (Winters-
82 Stone, Horak et al. 2017), or an unknown factor (Riskowski, Quach et al. 2012). The prevalence of
83 PN in the US population for those over age 40 is nearly 15% (Gregg, Sorlie et al. 2004) and 28.4% in
84 persons with diabetes (Hicks, Wang et al. 2021). The incidence of injuries due to falls is 15 times
85 higher in patients with diabetic PN than in healthy individuals (Cavanagh, Derr et al. 1992).
86 Furthermore, polyneuropathy contributes independently to functional impairments, including
87 difficulty walking and a tendency to fall (Hoffman, Staff et al. 2015), and those individuals more
88 often incur fall-related injuries (Hanewinkel, Drenthen et al. 2017). A prospective study of older
89 individuals with PN found that 65% fell during a one-year period and 30% reported an injury from a
90 fall (DeMott, Richardson et al. 2007).

91
92 Mechanoreceptors play an important role in proprioception (Fallon, Bent et al. 2005, Vaughan 2021)
93 and loss of sensory information from the lower limbs, including plantar mechanoreceptors alters
94 balance performance (Meyer, Oddsson et al. 2004, Meyer, Oddsson et al. 2004). Furthermore, this
95 sensory impairment affects the automaticity of walking, thereby increasing the need for cognitive
96 attention to gait and mobility activities (Paul, Ada et al. 2005, Clark, Christou et al. 2014, Clark

Extended Effects of a Wearable Sensory Prosthesis

97 2015). Furthermore, several studies have reported problems with gait and balance function and the
98 increased risk of falls in patients with PN (Menz, Lord et al. 2004, DeMott, Richardson et al. 2007,
99 Dixon, Knight et al. 2017, Lipsitz, Manor et al. 2018).

100
101 Additionally, low gait speed is a risk factor for falls (Studenski, Perera et al. 2003, Montero-Odasso,
102 Schapira et al. 2005), is an indicator of frailty (Kim, Glynn et al. 2019), and is even a predictor of
103 hospitalization and disability (Cesari, Kritchevsky et al. 2005, Dumurgier, Elbaz et al. 2009) as well
104 as survival (Studenski, Perera et al. 2011). In fact, interventions designed to improve gait speed may
105 actually increase survival (Hardy, Perera et al. 2007). Older adults with sensory impairment related to
106 PN show a decline in gait speed that is four times higher than in healthy aging (Buracchio, Dodge et
107 al. 2010, Lipsitz, Manor et al. 2018).

108
109 Although strength and balance training in patients with PN may help reduce fall risk falls (Ites,
110 Anderson et al. 2011, Tofthagen, Visovsky et al. 2012, Streckmann, Zopf et al. 2014, Morrison,
111 Simmons et al. 2018), strength training in patients with PN appears to have less impact on balance
112 (Streckmann, Zopf et al. 2014). Its effects are mainly compensatory and do not address impaired
113 somatosensation, the root cause of balance problems related to PN. Furthermore, balance training
114 activities must be specific (Oddsson, Boissy et al. 2007) and must be conducted with sufficient
115 intensity and frequency (Lipsitz, Macklin et al. 2019) to be helpful, or benefits will be limited or
116 absent (Kruse, Lemaster et al. 2010, Lipsitz, Manor et al. 2018, Lipsitz, Macklin et al. 2019). Clear
117 guidelines regarding frequency of balance exercises are currently lacking although three sessions a
118 week may be a minimum necessary to see an improvement (Kruse, Lemaster et al. 2010). Thus,
119 although “Falls can be prevented” (CDC 2021), they continue to be a large problem in older adults,
120 indicating a continued need for novel solutions.

121
122 We recently reported from our multi-site clinical trial (walk2Wellness, NCT #03538756,
123 www.clinicaltrials.gov) that individuals with PN and a high risk of falls improved their Functional
124 Gait Assessment (FGA) scores, (Wrisley, Marchetti et al. 2004), Gait Speed, and Timed Up & Go
125 times following 10 weeks of home-based use of a wearable sensory prosthesis intended to substitute
126 nerve function related to impaired plantar sensation (Figure 1, Walkasins by RxFunction Inc., Eden
127 Prairie, MN, USA), (Oddsson, Bisson et al. 2020). Previously, we found similar meaningful
128 improvements in FGA scores and gait speed in participants with PN in a randomized crossover trial
129 conducted in-clinic (Koehler-McNicholas, Danzl et al. 2019), findings that were recently referred to
130 as “presumably emulating” signals by fast-adapting cutaneous afferents (Vaughan 2021). We also
131 reported a decrease in the number of fall risk factors as well as fall rate from baseline to 10 weeks for
132 individuals who reported falls in the six months preceding study participation (Oddsson, Bisson et al.
133 2020).

134
135 Here we report extended long-term use data from the walk2Wellness trial for 44 participants after 26
136 weeks of Walkasins use. Furthermore, we analyzed falls during the 26 weeks of device use and
137 compared to patient self-reports of falls from the six months preceding participation in the study. We
138 expected improvements in clinical outcomes and lower fall rate seen after 10 weeks (Oddsson,
139 Bisson et al. 2020) to be sustained at 26 weeks.

140
141
142

143 2 Materials and Methods

144 Detailed descriptions of materials and methods have been reported previously (Oddsson, Bisson et al.
145 2020), and are summarized below. The measures we use have been validated (Oddsson, Bisson et al.
146 2020) and our primary outcome measure, the FGA, is recommended for assessment of walking
147 balance in adults with neurologic conditions by current physical therapy Clinical Practice Guidelines
148 (Moore, Potter et al. 2018). The walk2Wellness study is registered at ClinicalTrials.gov
149 (#NCT03538756). Figure 1 shows a picture of the Walkasins device components with a brief
150 description of its functionality.

151

152 2.1 Participants

153 The walk2Wellness clinical trial received approval for human subject research from Advarra IRB
154 (formerly Quorum Review) for four sites and from the IRB Subcommittee, the Subcommittee on
155 Research Safety, and the Research and Development Committee of the Minneapolis VA Health Care
156 System (MVAHCS). Recruitment for the walk2Wellness trial began in October 2018 and ended at
157 the last site in April 2021. Because of COVID-19 disruptions, the study ended earlier than planned at
158 four sites; the fifth site completed the trial but with a reduced enrollment goal. Study site team
159 members posted fliers at community businesses and clinics to advertise the trial; in addition, some of
160 the sites received referrals from physicians who were informed about the study.

161

162 To participate in the trial, individuals met the following inclusion criteria: male or female; ages 21-
163 90; a formal diagnosis of sensory PN prior to participating in the study as indicated by their medical
164 record or a letter by a physician; self-reported problems with balance; ability for transfers or
165 ambulation on level surfaces at fixed cadence as assessed by trained study personnel; FGA score <23,
166 the cut-off score for high fall risk (Wrisley and Kumar 2010); ability to understand and provide
167 informed consent; foot size to allow the Walkasins device to function properly, and ability to
168 complete all functional outcome measures without the use of an assistive device in order to ensure
169 sufficient motor function. Participants could use an assistive device at their discretion during their
170 daily activities.

171

172 Individuals were excluded if they were unable to perceive the tactile stimuli from the Walkasins Leg
173 Unit (Figure 1) or if they used an ankle-foot orthosis for ambulation that prevented donning the
174 device. In addition, individuals having any of the following conditions were excluded from
175 participation: acute thrombophlebitis; deep vein thrombosis; untreated lymphedema; a lesion of any
176 kind, swelling, infection, inflamed area of skin, or eruptions on the lower leg near placement of the
177 device; foot or ankle fractures; severe peripheral vascular disease; or any musculoskeletal or
178 neurological condition that would prohibit use of the device, as determined by a clinician. Because of
179 a potential to overload the pressure sensors in the foot pad, individuals weighing over 136 kg (300
180 lbs) were excluded from participation. The criteria to participate in the study were similar to
181 receiving a prescription for the device in a clinic. Potential participants also agreed not to initiate any
182 balance training (e.g., Tai-Chi, etc.) or balance-related therapy during the first 10 weeks of the trial
183 (Oddsson, Bisson et al. 2020). Furthermore, participants were blinded to their outcomes during the
184 trial and not shared by study personnel.

185

186 2.2 Study Procedures and Outcome Measures

187 Before undergoing any study-related procedures, individuals signed the IRB-approved consent form
188 and HIPAA authorization. After enrollment, site staff tested whether participants were able to
189 perceive the tactile stimuli from the Walkasins Leg Unit. Anyone unable to feel the tactile stimuli

Extended Effects of a Wearable Sensory Prosthesis

190 was excluded from continued participation in the study. Individuals who were able to feel the tactile
191 stimuli from the Walkasins Leg Unit bilaterally then completed a medical history form to assess
192 common health issues and systemic diseases. They also provided information on falls they had
193 experienced in the previous six and twelve months, including the number of falls and any injuries
194 they sustained as a result. In addition, participants provided a list of their medications (medication
195 name, indication, dose, and frequency), which was updated over the course of the study.

196
197 Participants then completed the Activities-Specific Balance Confidence (ABC) Questionnaire
198 (Powell and Myers 1995) to assess levels of balance self-confidence and the Vestibular Activities of
199 Daily Living Scale (VADL), (Cohen, Kimball et al. 2000) to evaluate the effects of vertigo and
200 balance disorders on their ability to perform everyday activities independently. At baseline, week 10,
201 and week 26, site personnel also assessed participants using the Weinstein Enhanced Sensory Test
202 (WEST) monofilament foot test (0.5g, 2g, 10g, 50g, and 200g), as described previously (Oddsson,
203 Bisson et al. 2020). Staff also performed a vibration sensation test using a Rydel-Seiffer Tuning Fork
204 to document loss of sensation (Kästenbauer, Sauseng et al. 2004, Oddsson, Bisson et al. 2020).
205 Scoring values ≤ 4 at the first metatarsal joint is categorized as abnormal (Kästenbauer, Sauseng et al.
206 2004).

207
208 During the baseline visit, participants donned the Walkasins devices and performed a standardized
209 set of standing and walking balance activities focused on orientation and familiarization with the
210 device, referred to as the Walkasins Learning Protocol (Koehler-McNicholas, Danzl et al. 2019,
211 Oddsson, Bisson et al. 2020). Trained site personnel then assessed participants on the FGA, 10-Meter
212 Walk Test (Perera, Mody et al. 2006), Timed Up & Go (TUG) (Mathias, Nayak et al. 1986), and 4-
213 Stage Balance Test (CDC 2021). The clinical outcomes were standardized and performed by study
214 personnel who were trained by one of the investigators (DW). A sponsor representative conducted
215 observation visits periodically during the study to ensure standardization across the sites (LJ).

216
217 After finishing the clinical outcome tests, participants completed the following self-reported outcome
218 measures to provide information about their quality of life, pain level, and engagement in social
219 activities: Patient Health Questionnaire (PHQ-9) (Kroenke, Spitzer et al. 2001), PROMIS Pain
220 Interference Short Form 6b (Askew, Cook et al. 2016), PROMIS Pain Intensity Form 1a, Ability to
221 Participate Short Form 8a (Hahn, Kallen et al. 2016), and Satisfaction with Participation in Social
222 Roles Short Form 8a (Hahn, DeWalt et al. 2014, Hahn, Beaumont et al. 2016). At the conclusion of
223 the baseline visit, site staff members trained the participants on caring for the device.

224
225 Participants left the baseline visit with the device and a calendar on which to note any fall events they
226 experienced as well as their use of Walkasins. For consistency across sites, we used the World Health
227 Organization's definition of a "fall": "A fall is an event which results in a person coming to rest
228 inadvertently on the ground or floor or other lower level." When participants reported falls, study
229 staff recorded the following: the fall date; severity (no injury, minor injury, or major injury); the level
230 of treatment the individual sought or received, if any; the cause or causes of the fall (environmental
231 factor, lost balance, lost consciousness, lost strength/felt weak, slipped, tripped, on new medication,
232 other, unknown); and a description of the fall.

233
234 Unless prevented from doing so because of COVID-19 site restrictions, participants returned for in-
235 person visits at weeks 2, 6, 10, and 26. These visits followed most of the same procedures as the
236 baseline visit: balance questionnaires, clinical assessments, and self-reported outcome measures. As
237 we have previously reported (Oddsson, Bisson et al. 2020) we calculated ABC to FGA ratios at each

Extended Effects of a Wearable Sensory Prosthesis

238 assessment to measure the degree of internal self-perception of balance capability (ABC score) in
239 relation to the externally observed walking balance performance (FGA score). We noted that a ratio
240 of around 3.3 would be “expected” based on the maximum scores of the two scales. This construct
241 aligns with a multifactorial causation model for falls emphasizing the importance of a “Realistic
242 Appraisal of One’s Own Abilities”, (Hadjistavropoulos, Delbaere et al. 2011).

243
244 Between the in-person visits at weeks 10 and 26, study sites contacted participants via telephone at
245 weeks 14, 18, and 22 to remind them of study requirements and to collect follow-up information
246 regarding health changes, falls, adverse events, pain scores, device usage, and device functioning, as
247 well as whether they had begun any physical therapy for their balance problems. If participants
248 reported adverse events and/or falls during these contacts, site personnel recorded the details on the
249 appropriate case report forms in REDCap Cloud, the electronic data capture system used in the study
250 (<https://www.redcapcloud.com/>, Encinitas, CA, United States).

251 **2.1 Statistical Analysis and Availability of Data**

252 An analysis of outcomes after 2, 6, and 10 weeks, with 10 weeks being the primary endpoint, was
253 presented earlier (Oddsson, Bisson et al. 2020). Here we focus on outcomes after extended long-term
254 device use and compare outcomes to baseline for individuals participating in 26 weeks of device use.
255 Graphical data from 2, 6 and 10 weeks are provided below for illustration. We calculated descriptive
256 statistics (mean and standard deviation or median as appropriate) for all variables and tested for
257 normality with the Shapiro-Wilk’s test. We applied the two-proportion Z-test to compare proportion-
258 based measures. We conducted a post-hoc analysis to compare participants at baseline who reported
259 falls in the previous six months (Pre-Fallers, n=25) to those who did not (Pre-NonFallers, n=19).
260 Their baseline characteristics were compared using a t-test for independent samples or a Mann-
261 Whitney U test if data was not normally distributed based on a Shapiro-Wilk’s test.

262
263 To compare baseline variables to those after 26 weeks of device use, we conducted a t-test for
264 dependent samples or Wilcoxon signed-rank test in case variables were not normally distributed. We
265 applied a Bonferroni’s adjustment of significance levels for correlated measures, ranging from
266 $p < 0.0167$ ($0.05/3$ for three comparisons) for a full correction (non-correlated measures, $r=0$) and
267 $p < 0.05$ for perfectly correlated measures ($r=1$) (Uitenbroek 1997). We calculated effect sizes using
268 Cohen’s d_{fm} according to recommendations by Lakens (Lakens 2013) and interpreted them according
269 to Cohen (Cohen 1988), i.e. 0.2 represents a small effect, 0.5 a medium effect, and 0.8 a large effect
270 size. Ninety-five percent confidence intervals of effect sizes were estimated according to Algina
271 (Algina, J et al. 2005).

272
273 We performed statistical analysis with the Analysis-ToolPak module in Microsoft Excel 2016 and the
274 Real Statistics Resource Pack software, release 6.8 (Zaiontz 2020). Baseline characteristics of
275 participants in the study from the four clinical sites are presented in Table 1. We have pooled the data
276 for the continued analysis presented here. The raw data supporting the conclusions of this article will
277 be made available to qualified researchers without undue reservation.

278
279

280 **3 Results**

281 **3.1 Enrollment and Allocation**

282 Our previous report with 45 participants at the 10 week primary endpoint (Oddsson, Bisson et al.
283 2020) was published early due to the unknown circumstances at the time related to COVID-19,
284 which had caused recruitment holds and suspension of in-person testing activities at the research
285 sites. Over time, the trial continued with the enrollment of additional participants who are part of the
286 current report as illustrated in the flow chart in Figure 2. Figure 2 shows the flow chart for the study
287 as it was continued from the 10-week primary endpoint assessment that we have previously reported
288 (Oddsson, Bisson et al. 2020). Text boxes with dashed lines in Figure 2 indicate enrollment numbers
289 for the initial 10-week report.

290
291 Of the 85 individuals who were assessed for eligibility, a total of 69 participants were enrolled in the
292 trial (17 more than in previous report, cf. Figure 2). Sixty participants took part in the 2-week follow
293 up visit, 55 in the 6-week follow-up visit, and 51 in the 10-week follow-up visit (six more than in the
294 previous report). Eleven of the 18 participants who discontinued interventions through the 10-week
295 follow-up visit stopped participation due to circumstances related to COVID-19 (cf. Figure 2). (Note:
296 due to the timing of study initiation at Johns Hopkins and the onset of the pandemic, the three
297 participants enrolled at the site were unable to complete most in-person assessments. When the
298 situation did not improve, the sponsor decided to terminate Johns Hopkins as a research site. None of
299 the participants had completed follow-up datasets through week 10, so their results were not included
300 in this analysis.)

301
302 Forty-four of the 51 participants who reached the 10-week follow-up assessment were analyzed after
303 their 26-week assessment. Due to circumstances related to COVID-19, including lockdowns at the
304 research sites, 14 of the 44 participants were unable to participate in the 26-week in-person outcomes
305 testing (FGA, 10MWT, TUG, and 4-Stage Balance Test). All 44 participants, however, were
306 assessed on self-reported outcomes over the phone, and all 44 participants provided reports of falls
307 throughout the 26-week period. Consequently, we report baseline assessment of clinical outcomes for
308 all 44 participants, comparing those who reported falling in the prior six months (Pre-Fallers) to those
309 who did not (Pre-NonFallers). We also present data over time for the 30 participants who completed
310 the 26-week in-person assessment (weeks 0, 2, 6, 10 and 26, Figure 2), comparing the baseline
311 assessments of those 30 participants to their 26-week assessment.

312
313 Seven of the 44 participants discontinued the intervention after the 10-week assessment (cf. Figure
314 2); one passed away; two had been enrolled in solely the 10-week protocol; three expressed device
315 dissatisfaction, and one experienced an unrelated adverse event.

316 **3.2 Baseline Characteristics and Outcomes**

317 Baseline characteristics for the 44 individuals who were evaluated at 26 weeks are shown in Table 1
318 and were substantially similar to those reported previously (Oddsson, Bisson et al. 2020). Participants
319 across all sites were pooled for the continued analysis.

320
321 The baseline characteristics of the 44 participants are shown in Table 2. Characteristics are also
322 reported separately for participants who reported falling in the six months preceding the study (Pre-F,
323 n=25) and participants who did not report a fall (Pre-NF, n=19). Overall, characteristics reported
324 previously for participants entering the trial were maintained (Oddsson, Bisson et al. 2020) except for

Extended Effects of a Wearable Sensory Prosthesis

325 some substantiated differences between the Pre-F and Pre-NF participants that were now statistically
326 significant (Table 2). In addition to previous observations, baseline self-selected gait speed and ABC
327 scores were significantly different between the Pre-F and Pre-NF groups, 0.83 m/s vs. 0.97 m/s and
328 57.8% vs. 69.6%, respectively (Table 2). A higher observed mean value in PHQ-9 score for the Pre-F
329 group was nearly statistically significant (5.7 vs. 3.3, respectively, $p=0.052$). Mean values for all
330 PROMIS measures were near 50, and any differences were well within 10 (Table 2) corresponding to
331 one standard deviation for these measures, indicating any observed differences were minor (Askew,
332 Cook et al. 2016, Hahn, Beaumont et al. 2016, Hahn, Kallen et al. 2016).

333 3.3 Clinical Outcomes

334 Improvements in FGA scores were seen across all individuals, irrespective of their baseline FGA
335 scores and appeared similar after 2-, 6-, 10- and 26-weeks of device use (Figure 3). This finding is
336 indicated by the regression lines in Figure 3 being shifted above the line of equality. Figure 3 also
337 illustrates similar improvements in FGA scores for the Pre-F group and the Pre-NF group (filled vs.
338 open symbols). Interestingly, the slope of the regression line was <1 at all assessments indicating
339 larger improvements in the lower range of baseline FGA scores mostly representing Pre-F group
340 participants (cf. Table 3 and further below). After 26 weeks of device use, FGA scores increased
341 across all individuals from 15.0 to 19.2 ($p<0.00001$, Table 3) indicating a large effect size (Cohen's
342 $d_{rm}=1.38$, Table 3). Furthermore, self-selected gait speed increased from 0.89 m/s to 0.97 m/s
343 ($p=0.02$), a medium effect size (Cohen's $d_{rm}=0.49$); and the 4-Stage Balance Test improved from
344 25.6 s to 28.4 s ($p<0.01$), representing a small effect size (Cohen's $d_{rm}=0.32$). An increase seen in fast
345 gait speed (1.30 m/s to 1.37 m/s) did not reach statistical significance ($p=0.07$). Changes in Rydel-
346 Seiffert tuning fork testing scores suggested a small decrease in sensitivity at the site of the lateral
347 malleolus (mean 3.8 to 3.2, $p=0.032$, Cohen's $d_{rm}=0.32$), while a noted decrease at the MTP joint did
348 not reach statistical significance ($p=0.07$).

349
350 The Pre-F cohort ($n=18$) improved their mean FGA score from 13.7 at baseline to 18.1 at 26 weeks
351 ($p<0.0001$, Table 3) representing a large effect size (Cohen's $d_{rm}=1.58$). Their observed increases in
352 self-selected gait speed from 0.82 m/s to 0.90 m/s and from 1.13 m/s to 1.23 m/s for fast gait speed
353 did not reach statistical significance ($p=0.12$ and $p=0.07$, respectively). The Pre-F group showed a
354 decrease in vibration sensation at the first MTP joint (mean 2.9 to 1.8, $p<0.005$) and at the lateral
355 malleolus that did not reach statistical significance (mean 3.75 to 3.25, $p=0.07$).

356
357 The Pre-NF group ($n=12$) increased their mean FGA score from 17.0 at Baseline to 20.8 at 26 weeks
358 ($p<0.004$, Cohen's $d_{rm}=1.23$, Table 3). A small increase in self-selected gait speed from 1.00 m/s to
359 1.08 m/s did not reach statistical significance ($p=0.06$). Other clinical outcomes, including Rydel-
360 Seiffert tuning fork sensitivity testing scores, remained unchanged at 26 weeks compared to baseline
361 (Table 3).

362
363 The mean values of all in-person outcomes across the 26 weeks of device use for all participants are
364 depicted in Figure 4 and are shown separately for the Pre-F and the Pre-NF groups. In general, the
365 behavior over time of the two subgroups was qualitatively similar, although the Pre-NF group
366 consistently performed better than the Pre-F cohort.

367 3.4 Self-reported Outcomes, Device Use and ABC to FGA ratios

368 Self-reported outcomes for the 44 participants who completed assessments through 26 weeks are
369 shown in Table 4. Across all participants, a slight but statistically significant increase was seen in

Extended Effects of a Wearable Sensory Prosthesis

370 PROMIS Ability to Participate scores after 26 weeks of device use (49.9 to 52.6, $p < 0.05$). All
371 baseline values were maintained at 26 weeks for the Pre-F group while we noted an increase in the
372 PROMIS Satisfaction with Social Roles scores (49.9 to 55.5, $p < 0.006$) for the Pre-NF group.

373
374 Participants documented their weekly device use in a calendar and were asked to report it back
375 during phone calls at weeks 14, 18, 22 and 26. Their average reported weekly device use was 5.1 ± 0.4
376 days. Participants reporting that they used the device weekly either “Every Day” or “At least 5 Days”
377 was $71.8 \pm 10.5\%$. An average of $94.8 \pm 3.3\%$ of reporting participants stated they used the device “1-2
378 Days” or more per week.

379
380 We also sought to monitor participants’ self-perceived balance confidence (Lajoie and Gallagher
381 2004) in relation to their assessed gait function performance over time in the trial by measuring
382 changes in the ABC to FGA ratio, which is shown in Figure 5. Figure 5 illustrates two observations.
383 First, the ABC/FGA ratio for the overly confident individuals gradually decreased from high values
384 at baseline to week 6 when the ratio essentially aligned with the low self-confidence participants,
385 who maintained a consistent ABC/FGA ratio of about 3.5 throughout the 26 week period of the trial
386 (Figure 5, left y-axis). Second, both groups of participants increased their FGA scores in a similar
387 fashion although the overly confident participants showed higher levels of improvement in their FGA
388 scores (Figure 5, right y-axis).

389 **3.5 Falls Data**

390 Falls were reported throughout the 26-week period for all 44 participants and separately for the Pre-F
391 ($n=25$) and Pre-NF ($n=19$) groups, respectively (Table 5). The 44 participants reported a total of 53
392 falls over 6 months prior to participating in the trial while 39 falls were documented during the 26
393 weeks of the trial, corresponding to a pre-study mean fall rate of 6.7 falls/1000 patient days
394 (median=5.6 falls/1000 patient days) and a post study mean fall rate of 4.8 falls/1000 patient days
395 (median=0 falls/1000 patient days). Wilcoxon Signed Rank test was used to compare pre- and post-
396 study fall rates since the data was not normally distributed (Shapiro-Wilk W-statistic=0.82,
397 $p < 0.0001$). Across all participants, the median of the post-study fall rate was lower than the pre-study
398 fall rate (Table 5, $p=0.044$), reflecting a 28% decrease in fall rate. Of the 44 participants, 25 had
399 fallen in the past six months (Pre-F); and after 26 weeks, 20 of the 44 participants had reported
400 falling. Overall, 31 of the 39 falls required no treatment while eight falls (~20%) required treatment
401 with four of those (~10%) causing severe injury (two fractures) (Table 5).

402
403 The 25 participants in the Pre-F cohort reported 31 falls after 26 weeks compared to 53 falls pre-
404 study corresponding to a pre-study fall rate of 11.8 falls/1000 patient days (median=11.1), which
405 decreased to 6.7 falls/1000 patient days at 26 weeks (median=5.0), a 43% decrease in fall rate
406 ($p=0.0043$). Of the 25 Pre-F participants, 12 did not fall during the study, a 48% statistically
407 significant decrease in number of fallers ($p < 0.0001$). Of the 31 falls experienced by the Pre-F cohort,
408 six (~20%) required treatment (Table 5). Three of the four falls that led to severe injury occurred in
409 the Pre-F group.

410
411 Seven of the 19 Pre-NF participants reported falling during the trial ($p < 0.0001$) leading to an increase
412 in fall rate from zero to 2.3 falls/1000 patient days at 26 weeks that was statistically significant
413 ($p=0.023$). A total of eight falls were reported by the seven Pre-NF participants who fell during the
414 study (Table 5). Two of the eight falls in the group required treatment, and one fall led to a severe
415 injury.

416

Extended Effects of a Wearable Sensory Prosthesis

417 Figure 6 illustrates the cumulative sum of falls based on six-month pre-study fall reports from the
418 participants and the falls recorded by the Pre-F cohort during the trial. The 53 pre-study falls were
419 randomly distributed across the six-month pre-study period for illustration purposes since the exact
420 time of their occurrence prior to the trial were not known (see Figure 6). Note that 53 falls over a
421 period of six months corresponds to $53/180 \sim 0.29$ falls/day, which becomes the slope of the blue
422 regression line in Figure 6, irrespective of the random distribution of the pre-study falls. The in-study
423 falls are presented on the day they occurred according to participant reports (see Figure 6). The in-
424 study decrease of falls quantified in Table 5 can be visually observed over time in Figure 6 as a lower
425 slope for the best fit regression line (blue-dotted line pre-study vs. orange-dotted line in-study). It
426 should be noted that the lower slope appears to begin after about 20 days of device use.
427
428

429 4 Discussion

430 4.1 Key Findings

431 Walkasins is a device that provides mechanical tactile stimuli related to foot pressure for individuals
432 with PN and gait and balance problems. Overall, our findings from analyzing outcomes after 26
433 weeks of wearing Walkasins show that improvements in outcomes seen after 10 weeks of use are
434 sustained longer term (Oddsson, Bisson et al. 2020). The FGA score was improved from 15.0 at
435 baseline to 19.2 after 26 weeks of device use across all participants, a large effect size (Cohen's
436 $d_{rm}=1.38$) and an increase that is beyond the MCID for community-dwelling older adults (Beninato,
437 Fernandes et al. 2014). Interestingly, these improvements were seen for individuals across the full
438 range of baseline FGA scores, from the lowest of 7 to the highest of 22 (Figure 3) with a tendency to
439 be higher for individuals in the lower FGA range. Furthermore, similar improvements were seen for
440 the Pre-F and Pre-NF cohorts. Moreover, the 46% decrease in fall rate, compared to pre-study falls
441 we reported after 10 weeks of use, was sustained at 43% after 26 weeks, an important observation
442 further discussed below. Weekly device use continued to be high and similar to after 10 weeks (5.1
443 vs. 5.3 days/week, respectively (Oddsson, Bisson et al. 2020)).

444
445 All clinical outcomes improved compared to baseline, but changes in TUG and 4-Stage Balance did
446 not reach statistical significance, likely because the study was underpowered for these measures
447 (Table 3). Previous work has found that older individuals with diabetic PN walk slower than their
448 healthy cohort (Menz, Lord et al. 2004), and older adults with peripheral sensory impairment show a
449 0.046m/s/yr. decline in gait speed (Lipsitz, Manor et al. 2018). This decrease is more than 3.5 times
450 higher than declines reported in healthy aging (Buracchio, Dodge et al. 2010). With this in mind, it is
451 encouraging to report a statistically significant 0.08m/s increase in gait speed across all
452 participants in this trial, which is beyond a small meaningful change (0.05m/s) and close to the range
453 for a substantial meaningful change (0.10m/s) (Perera, Mody et al. 2006).

454
455 Participants had a decrease in sensitivity to vibration, an overall small decrease at the lateral
456 malleolus and a larger change at the MTP joint in the Pre-Faller group. Such changes did not occur at
457 the 10-week assessment (Oddsson, Bisson et al. 2020). This decrease in tuning fork vibration
458 perception may indicate a progression of some participants' PN and increased sensory loss. In spite
459 of such changes, none of the participants stated that they were unable to perceive the stimuli provided
460 by the device, suggesting they were still benefiting from its use as confirmed by improved clinical
461 outcomes.

462 4.2 Balance Exercise Interventions and their Limitations

463 We can compare our findings to interventions using different forms of physical exercise in patients
464 with PN since we see similar improvements in outcomes from simply wearing the device in the
465 current trial. Several review studies conclude that balance training is “the most effective exercise
466 intervention” (Ites, Anderson et al. 2011, Tofthagen, Visovsky et al. 2012, Streckmann, Zopf et al.
467 2014, Morrison, Simmons et al. 2018), while strength training in patients with PN appears to have
468 less impact on balance (Streckmann, Zopf et al. 2014), likely due to lack of specificity related to
469 balance (Oddsson, Boissy et al. 2007). Although such interventions may improve balance outcomes,
470 effects are essentially compensatory since they do not address the root cause of the balance problem
471 in these patients, namely their impaired plantar sensation due to PN. Furthermore, any exercise
472 activity would need to be maintained on a regular basis long-term or benefits would gradually be lost
473 (Melzer and Oddsson 2013, van Waart, Stuiver et al. 2015), sometimes referred to as the “use it or

Extended Effects of a Wearable Sensory Prosthesis

474 lose it” principle (Hart 2021). This phenomenon is problematic because individuals sometimes
475 become sedentary due to health problems unrelated to their balance disorders. Likewise, long-term
476 compliance with exercise interventions is a challenge, due to motivation or lack of safety resources,
477 and has been reported to be low with over half of participants not being compliant (Sluijs, Kok et al.
478 1993, Alexandre, Nordin et al. 2002), likely causing diminished benefits of the exercise intervention.
479

480 The improvements in clinical outcomes we report here, were gained from a single, brief training visit
481 on the use of the sensory prosthesis and then simply by wearing it during regular daily activities. By
482 comparison, obtaining the benefits of an exercise intervention requires the presence and engagement
483 by the individual, at multiple therapy visits. In fact, during the first 10 weeks of use, we prohibited
484 participants from joining in any physical therapy or balance-related exercise activities to help isolate
485 the effect of the device (Oddsson, Bisson et al. 2020). Knowing, however, that such interventions
486 may help improve gait and balance function (Toftagen, Visovsky et al. 2012), we felt it would
487 potentially be unsafe and even unethical to prevent participation in those activities beyond the
488 primary endpoint at 10 weeks. Therefore, to control for any potential effects of balance exercise
489 interventions, we asked participants during follow-up phone calls at 14, 18, and 22 weeks whether
490 they had begun any physical therapy for their balance problems. Not surprisingly, only one of the
491 participants answered “yes” to this question, emphasizing the above-mentioned challenge with
492 exercise engagement and compliance, and further suggesting that long-term use of the device was the
493 main cause of improvement in clinical outcomes.

494 **4.3 Exercise Dosing versus Daily Exposure from Sensory Prosthesis Use**

495 These improvements in clinical outcomes are not surprising, because the mechanisms for improved
496 gait and balance function from exercise interventions are different than the mechanisms for using a
497 sensory prosthesis to replace an important component of somatosensory balance input, in this case
498 from plantar mechanoreceptors (Meyer, Oddsson et al. 2004, Fallon, Bent et al. 2005, Strzalkowski,
499 Peters et al. 2018). Traditional balance training activities stimulate existing sensorimotor integration
500 by challenging function with a series of successively more difficult motor tasks. This kind of
501 treatment gradually improves performance based on important and well-known principles of training
502 (Oddsson, Boissy et al. 2007). Such improvement may be attributable to training of specific splinter
503 skills, and some improvement may be due to compensation for balance issues from impaired plantar
504 sensation or address other balance related impairments. Users of a sensory prosthesis, however,
505 receive new functional sensory stimuli on a nearly continuous basis that are highly specific to
506 standing and walking and replace their impaired sense; and these new stimuli provide sensory
507 information that the central nervous system expects to receive from the lower extremities during such
508 activities (Guertin 2012, Clark 2015).
509

510 To analyze this contrast further, a research trial of traditional balance training interventions typically
511 provides one-hour balance stimulation sessions about 2-3 times per week for 3-6 months e.g.
512 (Shumway-Cook, Gruber et al. 1997, Wolf, Feys et al. 2001, Wolf, Sattin et al. 2003, Li, Harmer et
513 al. 2005, Li and Manor 2010, Melzer and Oddsson 2013, Manor, Lough et al. 2014). Assuming 100%
514 compliance, this example would add up to an overall exercise dose of no more than 72 hours of
515 focused therapeutic balance stimulation over six months. In a typical therapy practice, the dose would
516 more likely be in the range of 8-40 hours, for several reasons (HS Cohen, EdD, OTR, personal
517 communication). Patients sometimes miss visits due to schedule conflicts. Patients may shorten the
518 total length of treatment either because they feel they have reached their maximum level of
519 improvement, because they dislike the hassle of taking the time for the therapy visit, or because they
520 cannot get transportation. In addition, some insurance programs may refuse to pay for more than a

Extended Effects of a Wearable Sensory Prosthesis

521 limited number of therapy visits. In the case of exposure to balance stimuli from a sensory prosthesis,
522 however, participants used the device on average 36.1 hours/week with more than 80% using the
523 device over 21 hours/week (Oddsson, Bisson et al. 2020). Over 26 weeks this use would amount to a
524 range from around 500 to almost 1000 hours of specific gait and balance stimulation, essentially an
525 order of magnitude higher than a regular balance training intervention. Furthermore, the device is
526 intended to be used on a continuous basis, which furthers compliance.

527
528 Participants may not be physically active and receiving sensory stimuli the entire abovementioned
529 time. However, they will regularly experience hundreds of specific balance stimuli/hour that are
530 intimately integrated into their regular standing and walking activities and that are likely to cause
531 related changes in balance behavior. Over time, this feedback may lead to a reweighting of sensory
532 information that is relevant for balance function (Sienko, Seidler et al. 2018), as has previously been
533 suggested in older adults performing in-home balance training using vibrotactile sensory stimulation
534 related to trunk tilt (Noohi, Kinnaird et al. 2017, Bao, Carender et al. 2018) further supported by
535 recently reported changes in brain connectivity (Bao, Noohi et al. 2022).

536
537 Interestingly, early observations from a pilot study of five participants in the cohort studied here, who
538 completed 26 weeks of device use, show neuroplastic changes in brain network connectivity related
539 to postural control and balance that were associated with improved changes in FGA scores (Hsu,
540 Iloputaife et al. 2021). This finding indicates a direct effect of the sensory prosthesis initiating plastic
541 changes related to sensorimotor interaction and postural control. Related observations on
542 sensorimotor neuroplastic effects associated with peripheral afferent activity have previously been
543 made following a novel amputation strategy, agonist-antagonist myoneural interface, intended to
544 maintain neuromuscular communication of the lost limb (Srinivasan, Tuckute et al. 2020). This
545 surgical technique intends to promote proprioceptive feedback and cause central sensorimotor plastic
546 changes that may facilitate control of a prosthetic limb (Srinivasan, Tuckute et al. 2020). In a similar
547 fashion, the current non-invasive sensory prosthesis is externally providing new tactile afference,
548 essentially through the same dermatomes that signaled plantar pressure information from
549 mechanoreceptors that have become functionally deafferented due to PN (Fallon, Bent et al. 2005,
550 Koehler-McNicholas, Danzl et al. 2019, Vaughan 2021).

551 **4.4 ABC to FGA Ratios, Self-Reported Outcomes and Device Use**

552 On the ABC, 67% is the cut-off for high-fall risk (Lajoie and Gallagher 2004). We previously
553 reported that participants with baseline ABC scores below 67% improved their ABC scores after 10
554 weeks of device use, whereas those with ABC scores above 67% did not, although both subgroups
555 improved their FGA scores (Oddsson, Bisson et al. 2020). Since these two categories of participants
556 had similar baseline FGA scores, the discrepancy in ABC scores led to seemingly high baseline ABC
557 to FGA ratios in participants with high ABC scores (Oddsson, Bisson et al. 2020) (Figure 5). We
558 posited that the high ratio individuals were either too confident or simply unaware of their abilities or
559 impairments, a construct that aligns with a proposed multifactorial causation model for falls
560 emphasizing the importance of a “Realistic Appraisal of One’s Own Abilities”, (Hadjistavropoulos,
561 Delbaere et al. 2011). This ratio indicates the degree of internal self-perception of balance capability
562 (ABC score) in relation to the externally observed performance (FGA score). A ratio of around 3.3
563 would be “expected” based on the maximum scores of the two scales (Powell and Myers 1995,
564 Wrisley and Kumar 2010). We further noted that after six weeks of device use, the overly confident
565 participants appeared to “normalize” their self-perception indicating a more sensible perception of
566 their abilities and align with those holding more expected ABC scores. This change was mainly due
567 to an improvement in their FGA score and a maintained or slightly decreased ABC score.

Extended Effects of a Wearable Sensory Prosthesis

568 We show here that this observation is preserved after 26 weeks of device use (Figure 5). This change
569 in self confidence is important because it is a fall risk factor. As the data suggest, this ratio is a
570 modifiable risk factor. Therefore, the ratio can and should be measured during studies of balance
571 interventions.

572
573 Furthermore, the current data (Figure 5) shows that the high-confidence individuals appear to
574 improve their FGA scores more than the low confidence individuals. Since the baseline FGA scores
575 were similar for these two cohorts, it could be argued that the higher balance-confidence individuals
576 may have “naturally” challenged themselves more in their daily activities, triggering a larger increase
577 in FGA score. Correspondingly, the low balance-confidence individuals may have “explored” their
578 improved functional capabilities less than the high confidence group leading to a less beneficial long-
579 term effect. We postulate that individuals with low balance confidence would potentially benefit
580 further from a guided interaction through physical and occupational therapy or other means, whereas
581 the high confidence individuals may be better at “self-coaching” their renewed capabilities.
582 Consequently, to provide an individually optimized rehabilitation strategy for falls prevention and
583 self-efficacy, clinicians should monitor outcomes that measure both balance outcomes and balance
584 confidence, similar to the ratio we have used to allow this construct to be investigated further
585 (Hadjistavropoulos, Delbaere et al. 2011, Soh, Tan et al. 2021).

586
587 Additional observations related to self-report measures were in line with our previous reporting
588 (Oddsson, Bisson et al. 2020), overall showing marginal changes and likely being less clinically
589 meaningful since they were near the average for the US population (Hahn, DeWalt et al. 2014,
590 Askew, Cook et al. 2016, Hahn, Beaumont et al. 2016, Hahn, Kallen et al. 2016). The continued high
591 level of device use, on average more than five days a week and over 70% of participants using it
592 every day or at least 5 days/week, suggests that users find the device helpful.

593 **4.5 Falls Data**

594 One of the most important findings from this trial is the 43% decrease in fall rate for participants with
595 a fall history following 26 weeks of device use. We reported an encouraging 46% decrease already
596 after 10 weeks of use (Oddsson, Bisson et al. 2020), while appreciating that 10 weeks would not be
597 long enough for a relevant comparison to six months of pre-study data. Consequently, the similar
598 statistically significant decrease after 26 weeks provides a stronger argument for a meaningful
599 decrease in falls. In fact, even including the pre-study non-fallers in the analysis showed a
600 statistically significant decrease in fall rate over 26 weeks of device use (Table 5). Note, however,
601 that fall rate was not a primary outcome in this trial. In fact, we gathered pre-study falls data
602 primarily as a means of describing our study population, and we monitored falls during the trial as a
603 subset of adverse events. Thus, we enrolled participants at high fall risk based on their FGA scores,
604 irrespective of whether or not they had fallen in the past. This procedure allowed us to conduct a
605 post-hoc analysis and investigate any trend in the data indicating an actual decrease in falls. A
606 comparison with historical self-report data on prior falls is far from ideal as compared to a parallel
607 arm trial with a control group, but other investigators have found that asking individuals to recall past
608 falls commonly leads to an underreporting of actual falls; even recalling the past 3 months led to 25%
609 underreporting of falls (Hannan, Gagnon et al. 2010), and 26% did not recall falls over the prior six
610 months (Cummings, Nevitt et al. 1988). Under such circumstances, the 43% decrease in falls
611 reported here probably underestimates the real effect.

612
613 The data on injuries reported from falls are probably clinically significant. Previous studies have
614 reported that 65% of older individuals with PN fell over a year with 30% reporting an injury from a

Extended Effects of a Wearable Sensory Prosthesis

615 fall (DeMott, Richardson et al. 2007). In a study of individuals with chemotherapy-induced PN, over
616 40% experienced falls, and more than 40% of falls resulted in an injury, two-thirds of which were
617 fractures (Komatsu, Yagasaki et al. 2019). In this study, 57% of participants reported falling in the
618 six months prior to the study while 45% fell during six months of the trial. Eight of the 39 falls
619 during the trial (20.5%) led to injuries where treatment was sought, half of those considered serious.
620 Consequently, both fall rate and injury rate are lower than previous reports of similar populations
621 (DeMott, Richardson et al. 2007, Komatsu, Yagasaki et al. 2019).

622 **4.6 Study Limitations**

623 This study had several limitations, as we have previously outlined (Oddsson, Bisson et al. 2020). It
624 was an unblinded, single arm trial. Our decision to conduct a single arm trial was based on several
625 factors, including previous results from an in-clinic randomized control cross-over trial showing
626 improved FGA scores when using the device turned on compared to off (Koehler-McNicholas, Danzl
627 et al. 2019). In addition, data from the first-in-human, long-term use study showed remarkable
628 improvements in clinical outcomes in a patient with PN using the device for a year following over
629 five months of balance physical therapy with limited improvement (Wrisley, McLean et al. 2021).
630 This individual continues to use the device daily, now for more than four years. Also, blinding
631 participants in a study using this kind of intervention is challenging and may not really be viable
632 unless some form of deception is used since a requirement to use the device is perceiving the tactile
633 stimuli (Oddsson, Bisson et al. 2020). Consequently, the most feasible placebo treatment for a control
634 group would likely be wearing a device that is non-functional.

635
636 An important strength of the trial includes our real-life inclusion/exclusion criteria that were
637 essentially the same as the requirements for receiving a prescription for the device outside of a
638 research trial. These requirements are aligned with the intentions of a pragmatic clinical trial to
639 advance applicability of study findings (Patsopoulos 2011, Gill, Bhasin et al. 2021). Only 7% of
640 participants (6 of 85) were excluded due to medical circumstances (Figure 2). We wanted the
641 participants to realistically reflect patients who are seen in the clinic, and we did not try to screen for
642 only those individuals who may be the best responders. In fact, our participants reported an average
643 of 8.3 chronic conditions, had multiple fall-risk factors, and polypharmacy (mean of 8 subscription
644 medications).

645
646 Furthermore, the long-term benefits we report here combined with the participants not receiving any
647 useful feedback about their outcomes or systematic encouragement during their assessments and
648 knowing that only one individual decided to participate in a balance therapy intervention, decreases
649 the chance these effects are placebo (Finniss, Kaptchuk et al. 2010, Enck, Bingel et al. 2013, Coste
650 and Montel 2017). A review of placebo effects in 47 randomized control trials found large effects in
651 subjective outcomes and small effects in clinical outcomes, which is the opposite of what we report
652 here, further suggesting effects are due to device use. Additional strengths include our use of
653 recommended standardized objective clinical outcome measures (Moore, Potter et al. 2018) and the
654 involvement of multiple clinical sites from different regions using different evaluators.

655 **5 Conclusion**

656 Patients with peripheral neuropathy who have gait and balance problems with a high risk of falls
657 including a history of falls improve their walking balance and decrease their fall rates from long-term
658 use of a wearable sensory prosthesis.

659 **6 Acknowledgments**

660 We thank Lori Danzl, Alexandria Lloyd, Christine Olney (Minneapolis Department of Veterans
661 Affairs Health Care System, Minneapolis, MN), Jackie Geiser, Tien Dat Nguyen, Delorianne Sander
662 (M Health Fairview, Minneapolis, MN), Nathan Silver (Baylor College of Medicine, Houston, TX),
663 Wanting Yu (Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Roslindale,
664 MA) for providing study coordination, participant recruitment and data gathering activities. We thank
665 Amy Gravely, MA, for input on statistical analysis and Annette Xenopoulos-Oddsson (University of
666 Minnesota, MN,), Dr. Lee Newcomer, and Dr. Steven Stern for reviewing drafts of the manuscript.
667 The manuscript was published as a MedRxiv preprint.

668 **7 Contribution to the Field Statement**

669 Falls in older adults continues to be a large problem with few solutions. Falls are associated with
670 enormous costs to society, individual suffering, and loss of quality of life. Peripheral neuropathy,
671 leading to nerve damage, is recognized as an independent risk factor for falls and is often related to
672 diabetes or chemotherapy treatment or is of unknown etiology. A common symptom involves
673 numbness and sensory loss in the feet that can directly cause falls. Here we report data after extended
674 long-term daily use of a wearable sensory prosthesis (Walkasins[®], RxFunction Inc., MN, USA) from
675 the multi-site clinical trial, walk2Wellness. The device provides directional tactile stimuli around the
676 ankle during standing and walking activities, reflecting changes in foot pressure related to balance.
677 Patients can then “feel” their feet in contact with the ground and notice body sway during standing
678 because the device replaces related aspects of their impaired afferent nerve function. Data after 26
679 weeks of use shows that previously reported improvements in clinical outcomes after 10 weeks of
680 use are sustained. In addition, we can now report a decrease in fall rate in individuals who reported
681 falling six months prior to participating in the study.

682 **8 References**

- 683 Alexandre, N. M., M. Nordin, R. Hiebert and M. Campello (2002). "Predictors of compliance with
684 short-term treatment among patients with back pain." *Rev Panam Salud Publica* **12**(2): 86-94.
- 685 Algina, J, H. J. Keselman and R. D. Penfield (2005). "Effect Sizes and their Intervals: The Two-
686 Level Repeated Measures Case." *Edu Psych Meas* **65**(April): 241–258.
- 687 Askew, R. L., K. F. Cook, D. A. Revicki, D. Cella and D. Amtmann (2016). "Evidence from diverse
688 clinical populations supported clinical validity of PROMIS pain interference and pain behavior." *J*
689 *Clin Epidemiol* **73**: 103-111.
- 690 Bao, T., W. J. Carender, C. Kinnaird, V. J. Barone, G. Peethambaran, S. L. Whitney, M. Kabeto, R.
691 D. Seidler and K. H. Sienko (2018). "Effects of long-term balance training with vibrotactile sensory
692 augmentation among community-dwelling healthy older adults: a randomized preliminary study." *J*
693 *Neuroeng Rehabil* **15**(1): 5.
- 694 Bao, T., F. Noohi, C. Kinnaird, W. J. Carender, V. J. Barone, G. Peethambaran, S. L. Whitney, R. D.
695 Seidler and K. H. Sienko (2022). "Retention Effects of Long-Term Balance Training with
696 Vibrotactile Sensory Augmentation in Healthy Older Adults." *Sensors (Basel)* **22**(8).
- 697 Beninato, M., A. Fernandes and L. S. Plummer (2014). "Minimal clinically important difference of
698 the functional gait assessment in older adults." *Phys Ther* **94**(11): 1594-1603.
- 699 Bergen, G., M. R. Stevens and E. R. Burns (2016). "Falls and Fall Injuries Among Adults Aged ≥65
700 Years - United States, 2014." *MMWR Morb Mortal Wkly Rep* **65**(37): 993-998.
- 701 Buracchio, T., H. H. Dodge, D. Howieson, D. Wasserman and J. Kaye (2010). "The trajectory of gait
702 speed preceding mild cognitive impairment." *Arch Neurol* **67**(8): 980-986.
- 703 Cavanagh, P. R., J. A. Derr, J. S. Ulbrecht, R. E. Maser and T. J. Orchard (1992). "Problems with gait
704 and posture in neuropathic patients with insulin-dependent diabetes mellitus." *Diabet Med* **9**(5): 469-
705 474.
- 706 CDC. (2017). "STEADI - Older Adult Fall Prevention." Retrieved May 5, 2018, 2018, from
707 <https://www.cdc.gov/steadi/materials.html>.
- 708 CDC. (2021). "Older Adult Fall Prevention." Retrieved November 1, 2021, 2021, from
709 <https://www.cdc.gov/falls/facts.html>.
- 710 Cesari, M., S. B. Kritchevsky, B. W. Penninx, B. J. Nicklas, E. M. Simonsick, A. B. Newman, F. A.
711 Tylavsky, J. S. Brach, S. Satterfield, D. C. Bauer, M. Visser, S. M. Rubin, T. B. Harris and M. Pahor
712 (2005). "Prognostic value of usual gait speed in well-functioning older people--results from the
713 Health, Aging and Body Composition Study." *J Am Geriatr Soc* **53**(10): 1675-1680.
- 714 Clark, D. J. (2015). "Automaticity of walking: functional significance, mechanisms, measurement
715 and rehabilitation strategies." *Front Hum Neurosci* **9**: 246.
- 716 Clark, D. J., E. A. Christou, S. A. Ring, J. B. Williamson and L. Doty (2014). "Enhanced
717 somatosensory feedback reduces prefrontal cortical activity during walking in older adults." *J*
718 *Gerontol A Biol Sci Med Sci* **69**(11): 1422-1428.
- 719 Cohen, H. S., K. T. Kimball and A. S. Adams (2000). "Application of the vestibular disorders
720 activities of daily living scale." *Laryngoscope* **110**(7): 1204-1209.
- 721 Cohen, J. (1988). *Statistical Power Analysis for the Behavioral Sciences*. New York, NY, Routledge
722 Academic.
- 723 Cohen, M. A., J. Miller, X. Shi, J. Sandhu and L. A. Lipsitz (2015). "Prevention Program Lowered
724 The Risk Of Falls And Decreased Claims For Long-Term Services Among Elder Participants."
725 *Health Aff (Millwood)* **34**(6): 971-977.
- 726 Coste, J. and S. Montel (2017). "Placebo-related effects: a meta-narrative review of
727 conceptualization, mechanisms and their relevance in rheumatology." *Rheumatology (Oxford)* **56**(3):
728 334-343.

Extended Effects of a Wearable Sensory Prosthesis

- 729 Cummings, S. R., M. C. Nevitt and S. Kidd (1988). "Forgetting falls. The limited accuracy of recall
730 of falls in the elderly." *J Am Geriatr Soc* **36**(7): 613-616.
- 731 DeMott, T. K., J. K. Richardson, S. B. Thies and J. A. Ashton-Miller (2007). "Falls and gait
732 characteristics among older persons with peripheral neuropathy." *Am J Phys Med Rehabil* **86**(2):
733 125-132.
- 734 Dixon, C. J., T. Knight, E. Binns, B. Ihaka and D. O'Brien (2017). "Clinical measures of balance in
735 people with type two diabetes: A systematic literature review." *Gait Posture* **58**: 325-332.
- 736 Dumurgier, J., A. Elbaz, P. Ducimetière, B. Tavernier, A. Alépérovitch and C. Tzourio (2009). "Slow
737 walking speed and cardiovascular death in well functioning older adults: prospective cohort study."
738 *BMJ* **339**: b4460.
- 739 Enck, P., U. Bingel, M. Schedlowski and W. Rief (2013). "The placebo response in medicine:
740 minimize, maximize or personalize?" *Nat Rev Drug Discov* **12**(3): 191-204.
- 741 Fallon, J. B., L. R. Bent, P. A. McNulty and V. G. Macefield (2005). "Evidence for strong synaptic
742 coupling between single tactile afferents from the sole of the foot and motoneurons supplying leg
743 muscles." *J Neurophysiol* **94**(6): 3795-3804.
- 744 Finnis, D. G., T. J. Kaptchuk, F. Miller and F. Benedetti (2010). "Biological, clinical, and ethical
745 advances of placebo effects." *Lancet* **375**(9715): 686-695.
- 746 Ganz, D. A. and N. K. Latham (2020). "Prevention of Falls in Community-Dwelling Older Adults."
747 *N Engl J Med* **382**(8): 734-743.
- 748 Gill, T. M., S. Bhasin, D. B. Reuben, N. K. Latham, K. Araujo, D. A. Ganz, C. Boult, A. W. Wu, J.
749 Magaziner, N. Alexander, R. B. Wallace, M. E. Miller, T. G. Trivison, S. L. Greenspan, J. H.
750 Gurwitz, J. Rich, E. Volpi, S. C. Waring, T. M. Manini, L. C. Min, J. Teresi, P. C. Dykes, S.
751 McMahon, J. M. McGloin, E. A. Skokos, P. Charpentier, S. Basaria, P. W. Duncan, T. W. Storer, P.
752 Gazarian, H. G. Allore, J. Dziura, D. Esserman, M. B. Carnie, C. Hanson, F. Ko, N. M. Resnick, J.
753 Wiggins, C. Lu, C. Meng, L. Goehring, M. Fagan, R. Correa-de-Araujo, C. Casteel, P. Peduzzi and
754 E. J. Greene (2021). "Effect of a Multifactorial Fall Injury Prevention Intervention on Patient Well-
755 Being: The STRIDE Study." *J Am Geriatr Soc* **69**(1): 173-179.
- 756 Gregg, E. W., P. Sorlie, R. Paulose-Ram, Q. Gu, M. S. Eberhardt, M. Wolz, V. Burt, L. Curtin, M.
757 Engelgau, L. Geiss and -. n. h. a. n. e. survey (2004). "Prevalence of lower-extremity disease in the
758 US adult population ≥ 40 years of age with and without diabetes: 1999-2000 national health and
759 nutrition examination survey." *Diabetes Care* **27**(7): 1591-1597.
- 760 Guertin, P. A. (2012). "Central pattern generator for locomotion: anatomical, physiological, and
761 pathophysiological considerations." *Front Neurol* **3**: 183.
- 762 Hadjistavropoulos, T., K. Delbaere and T. D. Fitzgerald (2011). "Reconceptualizing the role of fear
763 of falling and balance confidence in fall risk." *J Aging Health* **23**(1): 3-23.
- 764 Hahn, E. A., J. L. Beaumont, P. A. Pilkonis, S. F. Garcia, S. Magasi, D. A. DeWalt and D. Cella
765 (2016). "The PROMIS satisfaction with social participation measures demonstrated responsiveness in
766 diverse clinical populations." *J Clin Epidemiol* **73**: 135-141.
- 767 Hahn, E. A., D. A. DeWalt, R. K. Bode, S. F. Garcia, R. F. DeVellis, H. Correia, D. Cella and P. C.
768 Group (2014). "New English and Spanish social health measures will facilitate evaluating health
769 determinants." *Health Psychol* **33**(5): 490-499.
- 770 Hahn, E. A., M. A. Kallen, R. E. Jensen, A. L. Potosky, C. M. Moinpour, M. Ramirez, D. Cella and
771 J. A. Teresi (2016). "Measuring social function in diverse cancer populations: Evaluation of
772 measurement equivalence of the Patient Reported Outcomes Measurement Information System."
773 *Psychol Test Assess Model* **58**(2): 403-421.
- 774 Halvarsson, A., E. Franzén, E. Farén, E. Olsson, L. Oddsson and A. Ståhle (2013). "Long-term
775 effects of new progressive group balance training for elderly people with increased risk of falling - a
776 randomized controlled trial." *Clin Rehabil* **27**(5): 450-458.

Extended Effects of a Wearable Sensory Prosthesis

- 777 Hanewinkel, R., J. Drenthen, V. J. A. Verlinden, S. K. L. Darweesh, J. N. van der Geest, A.
778 Hofman, P. A. van Doorn and M. A. Ikram (2017). "Polyneuropathy relates to impairment in daily
779 activities, worse gait, and fall-related injuries." *Neurology* **89**(1): 76-83.
- 780 Hannan, M. T., M. M. Gagnon, J. Aneja, R. N. Jones, L. A. Cupples, L. A. Lipsitz, E. J. Samelson, S.
781 G. Leveille and D. P. Kiel (2010). "Optimizing the tracking of falls in studies of older participants:
782 comparison of quarterly telephone recall with monthly falls calendars in the MOBILIZE Boston
783 Study." *Am J Epidemiol* **171**(9): 1031-1036.
- 784 Hardy, S. E., S. Perera, Y. F. Roumani, J. M. Chandler and S. A. Studenski (2007). "Improvement in
785 usual gait speed predicts better survival in older adults." *J Am Geriatr Soc* **55**(11): 1727-1734.
- 786 Hart, D. A. (2021). "Learning From Human Responses to Deconditioning Environments: Improved
787 Understanding of the "Use It or Lose It" Principle." *Front Sports Act Living* **3**: 685845.
- 788 Hicks, C. W., D. Wang, B. G. Windham, K. Matsushita and E. Selvin (2021). "Prevalence of
789 peripheral neuropathy defined by monofilament insensitivity in middle-aged and older adults in two
790 US cohorts." *Sci Rep* **11**(1): 19159.
- 791 Hoffman, E. M., N. P. Staff, J. M. Robb, J. L. St Sauver, P. J. Dyck and C. J. Klein (2015).
792 "Impairments and comorbidities of polyneuropathy revealed by population-based analyses."
793 *Neurology* **84**(16): 1644-1651.
- 794 Hsu, C. L., I. Iloputaife, L. Oddsson, B. Manor and L. Lipsitz (2021). "Six-Month Lower-Leg
795 Sensory Stimulation Augments Neural Network Connectivity Associated With Improved Gait."
796 *Innovation in aging* **5**(Suppl 1): 960-961.
- 797 Ites, K. I., E. J. Anderson, M. L. Cahill, J. A. Kearney, E. C. Post and L. S. Gilchrist (2011). "Balance
798 interventions for diabetic peripheral neuropathy: a systematic review." *J Geriatr Phys Ther* **34**(3):
799 109-116.
- 800 Kim, D. H., R. J. Glynn, J. Avorn, L. A. Lipsitz, K. Rockwood, A. Pawar and S. Schneeweiss (2019).
801 "Validation of a Claims-Based Frailty Index Against Physical Performance and Adverse Health
802 Outcomes in the Health and Retirement Study." *J Gerontol A Biol Sci Med Sci* **74**(8): 1271-1276.
- 803 Koehler-McNicholas, S. R., L. Danzl, A. Y. Cataldo and L. I. E. Oddsson (2019). "Neuromodulation
804 to improve gait and balance function using a sensory neuroprosthesis in people who report insensate
805 feet - A randomized control cross-over study." *PLoS One* **14**(4): e0216212.
- 806 Komatsu, H., K. Yagasaki, Y. Komatsu, H. Yamauchi, T. Yamauchi, T. Shimokawa and A. Z.
807 Doorenbos (2019). "Falls and Functional Impairments in Breast Cancer Patients with Chemotherapy-
808 Induced Peripheral Neuropathy." *Asia Pac J Oncol Nurs* **6**(3): 253-260.
- 809 Koski, K., H. Luukinen, P. Laippala and S. L. Kivelä (1998). "Risk factors for major injurious falls
810 among the home-dwelling elderly by functional abilities. A prospective population-based study."
811 *Gerontology* **44**(4): 232-238.
- 812 Kroenke, K., R. L. Spitzer and J. B. Williams (2001). "The PHQ-9: validity of a brief depression
813 severity measure." *J Gen Intern Med* **16**(9): 606-613.
- 814 Kruse, R. L., J. W. Lemaster and R. W. Madsen (2010). "Fall and balance outcomes after an
815 intervention to promote leg strength, balance, and walking in people with diabetic peripheral
816 neuropathy: "feet first" randomized controlled trial." *Phys Ther* **90**(11): 1568-1579.
- 817 Kästenbauer, T., S. Sauseng, H. Brath, H. Abrahamian and K. Irsigler (2004). "The value of the
818 Rydel-Seiffer tuning fork as a predictor of diabetic polyneuropathy compared with a
819 neurothesiometer." *Diabet Med* **21**(6): 563-567.
- 820 Lajoie, Y. and S. P. Gallagher (2004). "Predicting falls within the elderly community: comparison of
821 postural sway, reaction time, the Berg balance scale and the Activities-specific Balance Confidence
822 (ABC) scale for comparing fallers and non-fallers." *Arch Gerontol Geriatr* **38**(1): 11-26.
- 823 Lakens, D. (2013). "Calculating and reporting effect sizes to facilitate cumulative science: a practical
824 primer for t-tests and ANOVAs." *Front Psychol* **4**: 863.

Extended Effects of a Wearable Sensory Prosthesis

- 825 Li, F., P. Harmer, K. J. Fisher, E. McAuley, N. Chaumeton, E. Eckstrom and N. L. Wilson (2005).
826 "Tai Chi and fall reductions in older adults: a randomized controlled trial." J Gerontol A Biol Sci
827 Med Sci **60**(2): 187-194.
- 828 Li, L. and B. Manor (2010). "Long term Tai Chi exercise improves physical performance among
829 people with peripheral neuropathy." Am J Chin Med **38**(3): 449-459.
- 830 Lipsitz, L. A., E. A. Macklin, T. G. Trivison, B. Manor, P. Gagnon, T. Tsai, I. I. Aizpurúa, O. Y. Lo
831 and P. M. Wayne (2019). "A Cluster Randomized Trial of Tai Chi vs Health Education in Subsidized
832 Housing: The MI-WiSH Study." J Am Geriatr Soc **67**(9): 1812-1819.
- 833 Lipsitz, L. A., B. Manor, D. Habtemariam, I. Iloputaife, J. Zhou and T. G. Trivison (2018). "The
834 pace and prognosis of peripheral sensory loss in advanced age: association with gait speed and falls."
835 BMC Geriatr **18**(1): 274.
- 836 Manor, B., M. Lough, M. M. Gagnon, A. Cupples, P. M. Wayne and L. A. Lipsitz (2014).
837 "Functional benefits of tai chi training in senior housing facilities." J Am Geriatr Soc **62**(8): 1484-
838 1489.
- 839 Mathias, S., U. S. Nayak and B. Isaacs (1986). "Balance in elderly patients: the "get-up and go" test."
840 Arch Phys Med Rehabil **67**(6): 387-389.
- 841 Melzer, I. and L. I. e. Oddsson (2013). "Improving balance control and self-reported lower extremity
842 function in community-dwelling older adults: a randomized control trial." Clin Rehabil **27**(3): 195-
843 206.
- 844 Menz, H. B., S. R. Lord, R. St George and R. C. Fitzpatrick (2004). "Walking stability and
845 sensorimotor function in older people with diabetic peripheral neuropathy." Arch Phys Med Rehabil
846 **85**(2): 245-252.
- 847 Meyer, P. F., L. I. Oddsson and C. J. De Luca (2004). "Reduced plantar sensitivity alters postural
848 responses to lateral perturbations of balance." Exp Brain Res **157**(4): 526-536.
- 849 Meyer, P. F., L. I. Oddsson and C. J. De Luca (2004). "The role of plantar cutaneous sensation in
850 unperturbed stance." Exp Brain Res **156**(4): 505-512.
- 851 Montero-Odasso, M., M. Schapira, E. R. Soriano, M. Varela, R. Kaplan, L. A. Camera and L. M.
852 Mayorga (2005). "Gait velocity as a single predictor of adverse events in healthy seniors aged 75
853 years and older." J Gerontol A Biol Sci Med Sci **60**(10): 1304-1309.
- 854 Montero-Odasso, M. M., N. Kamkar, F. Pieruccini-Faria, A. Osman, Y. Sarquis-Adamson, J. Close,
855 D. B. Hogan, S. W. Hunter, R. A. Kenny, L. A. Lipsitz, S. R. Lord, K. M. Madden, M. Petrovic, J.
856 Ryg, M. Speechley, M. Sultana, M. P. Tan, N. van der Velde, J. Verghese, T. Masud and T. F. o. G.
857 G. f. F. i. O. Adults (2021). "Evaluation of Clinical Practice Guidelines on Fall Prevention and
858 Management for Older Adults: A Systematic Review." JAMA Netw Open **4**(12): e2138911.
- 859 Moore, J. L., K. Potter, K. Blankshain, S. L. Kaplan, L. C. O'Dwyer and J. E. Sullivan (2018). "A
860 Core Set of Outcome Measures for Adults With Neurologic Conditions Undergoing Rehabilitation: A
861 CLINICAL PRACTICE GUIDELINE." J Neurol Phys Ther **42**(3): 174-220.
- 862 Moreland, B., R. Kakara and A. Henry (2020). "Trends in Nonfatal Falls and Fall-Related Injuries
863 Among Adults Aged ≥ 65 Years - United States, 2012-2018." MMWR Morb Mortal Wkly Rep
864 **69**(27): 875-881.
- 865 Morris, S. B. and R. P. DeShon (2002). "Combining effect size estimates in meta-analysis with
866 repeated measures and independent-groups designs." Psychol Methods **7**(1): 105-125.
- 867 Morrison, S., R. Simmons, S. R. Colberg, H. K. Parson and A. I. Vinik (2018). "Supervised Balance
868 Training and Wii Fit-Based Exercises Lower Falls Risk in Older Adults With Type 2 Diabetes." J
869 Am Med Dir Assoc **19**(2): 185.e187-185.e113.
- 870 Mustapa, A., M. Justine, N. Mohd Mustafah, N. Jamil and H. Manaf (2016). "Postural Control and
871 Gait Performance in the Diabetic Peripheral Neuropathy: A Systematic Review." Biomed Res Int
872 **2016**: 9305025.

Extended Effects of a Wearable Sensory Prosthesis

- 873 Noohi, F., C. Kinnaird, Y. DeDios, I. S. Kofman, S. Wood, J. Bloomberg, A. Mulavara and R.
874 Seidler (2017). "Functional Brain Activation in Response to a Clinical Vestibular Test Correlates
875 with Balance." *Front Syst Neurosci* **11**: 11.
- 876 Oddsson, L. I. E., T. Bisson, H. S. Cohen, L. Jacobs, M. Khoshnoodi, D. Kung, L. A. Lipsitz, B.
877 Manor, P. McCracken, Y. Rumsey, D. M. Wrisley and S. R. Koehler-McNicholas (2020). "The
878 Effects of a Wearable Sensory Prosthesis on Gait and Balance Function After 10 Weeks of Use in
879 Persons With Peripheral Neuropathy and High Fall Risk - The walk2Wellness Trial." *Front Aging*
880 *Neurosci* **12**: 592751.
- 881 Oddsson, L. I. E., P. Boissy and I. Melzer (2007). "How to improve gait and balance function in
882 elderly individuals—compliance with principles of training." *Eur Rev Aging Phys Act* **Volume**
883 **4**(Issue 1): 15-23.
- 884 Patsopoulos, N. A. (2011). "A pragmatic view on pragmatic trials." *Dialogues Clin Neurosci* **13**(2):
885 217-224.
- 886 Paul, S. S., L. Ada and C. G. Canning (2005). "Automaticity of walking – implications for
887 physiotherapy practice." *Physical Therapy Reviews* **10**(1): 15-23.
- 888 Perera, S., S. H. Mody, R. C. Woodman and S. A. Studenski (2006). "Meaningful change and
889 responsiveness in common physical performance measures in older adults." *J Am Geriatr Soc* **54**(5):
890 743-749.
- 891 Powell, L. E. and A. M. Myers (1995). "The Activities-specific Balance Confidence (ABC) Scale." *J*
892 *Gerontol A Biol Sci Med Sci* **50A**(1): M28-34.
- 893 Quigley, P. A., T. Bulat, B. Schulz, Y. Friedman, S. Hart-Hughes, J. K. Richardson and S. Barnett
894 (2014). "Exercise interventions, gait, and balance in older subjects with distal symmetric
895 polyneuropathy: a three-group randomized clinical trial." *Am J Phys Med Rehabil* **93**(1): 1-12; quiz
896 13-16.
- 897 Reeves, N. D., G. Orlando and S. J. Brown (2021). "Sensory-Motor Mechanisms Increasing Falls
898 Risk in Diabetic Peripheral Neuropathy." *Medicina (Kaunas)* **57**(5).
- 899 Richardson, J. K. and E. A. Hurvitz (1995). "Peripheral neuropathy: a true risk factor for falls." *J*
900 *Gerontol A Biol Sci Med Sci* **50**(4): M211-215.
- 901 Richardson, J. K., D. Sandman and S. Vela (2001). "A focused exercise regimen improves clinical
902 measures of balance in patients with peripheral neuropathy." *Arch Phys Med Rehabil* **82**(2): 205-209.
- 903 Riskowski, J. L., L. Quach, B. Manor, H. B. Menz, L. A. Lipsitz and M. T. Hannan (2012).
904 "Idiopathic peripheral neuropathy increases fall risk in a population-based cohort study of older
905 adults." *Journal of Foot and Ankle Research* **5**(1): P19.
- 906 Sheldon, J. H. (1948). "Some aspects of old age." *Lancet* **1**(6504): 621-624.
- 907 Shumway-Cook, A., W. Gruber, M. Baldwin and S. Liao (1997). "The effect of multidimensional
908 exercises on balance, mobility, and fall risk in community-dwelling older adults." *Phys Ther* **77**(1):
909 46-57.
- 910 Sienko, K. H., R. D. Seidler, W. J. Carender, A. D. Goodworth, S. L. Whitney and R. J. Peterka
911 (2018). "Potential Mechanisms of Sensory Augmentation Systems on Human Balance Control." *Front Neurol* **9**: 944.
- 912 Sluijs, E. M., G. J. Kok and J. van der Zee (1993). "Correlates of exercise compliance in physical
913 therapy." *Phys Ther* **73**(11): 771-782; discussion 783-776.
- 914 Soh, S. L., C. W. Tan, J. I. Thomas, G. Tan, T. Xu, Y. L. Ng and J. Lane (2021). "Falls efficacy:
915 Extending the understanding of self-efficacy in older adults towards managing falls." *J Frailty*
916 *Sarcopenia Falls* **6**(3): 131-138.
- 917 Srinivasan, S. S., G. Tuckute, J. Zou, S. Gutierrez-Arango, H. Song, R. L. Barry and H. M. Herr
918 (2020). "Agonist-antagonist myoneural interface amputation preserves proprioceptive sensorimotor
919 neurophysiology in lower limbs." *Sci Transl Med* **12**(573).
- 920

Extended Effects of a Wearable Sensory Prosthesis

- 921 STEADI, C.-. (2021). "STEADI—Older Adult Fall Prevention." July 26, 2021. Retrieved December
922 10, 2021, 2021, from <https://www.cdc.gov/steady/>.
- 923 Stevens, J. A. and E. A. Phelan (2013). "Development of STEADI: a fall prevention resource for
924 health care providers." *Health Promot Pract* **14**(5): 706-714.
- 925 Streckmann, F., E. M. Zopf, H. C. Lehmann, K. May, J. Rizza, P. Zimmer, A. Gollhofer, W. Bloch
926 and F. T. Baumann (2014). "Exercise intervention studies in patients with peripheral neuropathy: a
927 systematic review." *Sports Med* **44**(9): 1289-1304.
- 928 Strzalkowski, N. D. J., R. M. Peters, J. T. Inglis and L. R. Bent (2018). "Cutaneous afferent
929 innervation of the human foot sole: what can we learn from single-unit recordings?" *J Neurophysiol*
930 **120**(3): 1233-1246.
- 931 Studenski, S., S. Perera, K. Patel, C. Rosano, K. Faulkner, M. Inzitari, J. Brach, J. Chandler, P.
932 Cawthon, E. B. Connor, M. Nevitt, M. Visser, S. Kritchevsky, S. Badinelli, T. Harris, A. B.
933 Newman, J. Cauley, L. Ferrucci and J. Guralnik (2011). "Gait speed and survival in older adults."
934 *JAMA* **305**(1): 50-58.
- 935 Studenski, S., S. Perera, D. Wallace, J. M. Chandler, P. W. Duncan, E. Rooney, M. Fox and J. M.
936 Guralnik (2003). "Physical performance measures in the clinical setting." *J Am Geriatr Soc* **51**(3):
937 314-322.
- 938 Tinetti, M. E. and C. Kumar (2010). "The patient who falls: "It's always a trade-off"." *JAMA* **303**(3):
939 258-266.
- 940 Toftagen, C., C. Visovsky and D. L. Berry (2012). "Strength and balance training for adults with
941 peripheral neuropathy and high risk of fall: current evidence and implications for future research."
942 *Oncol Nurs Forum* **39**(5): E416-424.
- 943 Uitenbroek, D. G. (1997). "SISA-Binomial." Retrieved May, 2020, from
944 <https://www.quantitativeskills.com/sisa/calculations/bonfer.htm>.
- 945 van Waart, H., M. M. Stuiver, W. H. van Harten, E. Geleijn, J. M. Kieffer, L. M. Buffart, M. de
946 Maaker-Berkhof, E. Boven, J. Schrama, M. M. Geenen, J. M. Meerum Terwogt, A. van Bochove, V.
947 Lustig, S. M. van den Heiligenberg, C. H. Smorenburg, J. A. Hellendoorn-van Vreeswijk, G. S.
948 Sonke and N. K. Aaronson (2015). "Effect of Low-Intensity Physical Activity and Moderate- to
949 High-Intensity Physical Exercise During Adjuvant Chemotherapy on Physical Fitness, Fatigue, and
950 Chemotherapy Completion Rates: Results of the PACES Randomized Clinical Trial." *J Clin Oncol*
951 **33**(17): 1918-1927.
- 952 Vaughan, G. M. (2021). "The roles of mechanoreceptors in muscle and skin in human
953 proprioception." *Current Opinion in Physiology* **21**: 48-56.
- 954 Vinik, A. I., P. Camacho, S. Reddy, W. M. Valencia, D. Trence, A. M. Matsumoto and J. E. Morley
955 (2017). "AGING, DIABETES, AND FALLS." *Endocr Pract* **23**(9): 1117-1139.
- 956 Wang, C., R. Goel, Q. Zhang, B. Lepow and B. Najafi (2019). "Daily Use of Bilateral Custom-Made
957 Ankle-Foot Orthoses for Fall Prevention in Older Adults: A Randomized Controlled Trial." *J Am*
958 *Geriatr Soc* **67**(8): 1656-1661.
- 959 Winters-Stone, K. M., F. Horak, P. G. Jacobs, P. Trubowitz, N. F. Dieckmann, S. Stoyles and S.
960 Faithfull (2017). "Falls, Functioning, and Disability Among Women With Persistent Symptoms of
961 Chemotherapy-Induced Peripheral Neuropathy." *J Clin Oncol* **35**(23): 2604-2612.
- 962 Wolf, B., H. Feys, De Weerd, J. van der Meer, M. Noom and G. Aufdemkampe (2001). "Effect of a
963 physical therapeutic intervention for balance problems in the elderly: a single-blind, randomized,
964 controlled multicentre trial." *Clin Rehabil* **15**(6): 624-636.
- 965 Wolf, S. L., R. W. Sattin, M. Kutner, M. O'Grady, A. I. Greenspan and R. J. Gregor (2003). "Intense
966 tai chi exercise training and fall occurrences in older, transitionally frail adults: a randomized,
967 controlled trial." *J Am Geriatr Soc* **51**(12): 1693-1701.

Extended Effects of a Wearable Sensory Prosthesis

- 968 Wrisley, D. M. and N. A. Kumar (2010). "Functional gait assessment: concurrent, discriminative, and
969 predictive validity in community-dwelling older adults." Phys Ther **90**(5): 761-773.
- 970 Wrisley, D. M., G. F. Marchetti, D. K. Kuharsky and S. L. Whitney (2004). "Reliability, internal
971 consistency, and validity of data obtained with the functional gait assessment." Phys Ther **84**(10):
972 906-918.
- 973 Wrisley, D. M., G. McLean, J. B. Hill and L. I. E. Oddsson (2021). "Long-Term Use of a Sensory
974 Prosthesis Improves Function in a Patient With Peripheral Neuropathy: A Case Report." Front Neurol
975 **12**: 655963.
- 976 Zaiontz, C. (2020). "Real Statistics Resource Pack (Release 6.8)." Release 6.8. from
977 <http://www.real-statistics.com/>.
978
979

Extended Effects of a Wearable Sensory Prosthesis

980

981 **Table 1.** Characteristics of the 44 individuals from the four different clinical sites enrolled in the study who reached 26
 982 weeks of participation. Values represent Mean (Standard Deviation). #ChrD - Number of Chronic Diseases.
 983

	n	Age (yrs)	Height (m)	Weight (kg)	#ChrD	FGA Score	Gait Speed Self-selected (m/s)	Gait Speed Fast (m/s)	TUG (s)	4-Stage Balance Test (s)	ABC Score
VAMC	18	74.4 (6.0)	1.76 (0.07)	96.9 (14.1)	9.6 (2.3)	15.4 (4.1)	0.82 (0.13)	1.27 (0.36)	13.5 (2.9)	24.8 (7.4)	68.2 (15.8)
Baylor	11	74.6 (9.4)	1.75 (0.08)	87.0 (15.2)	8.2 (2.9)	15.4 (4.5)	0.88 (0.25)	1.33 (0.39)	13.3 (6.3)	28.1 (8.0)	55.6 (18.8)
M Health Fairview	5	71.2 (10.7)	1.75 (0.14)	84.4 (12.0)	6.8 (5.3)	15.6 (2.1)	1.07 (0.21)	1.32 (0.20)	10.5 (1.4)	26.4 (3.8)	64.1 (7.0)
Harvard	10	71.5 (8.0)	1.76 (0.13)	86.7 (16.9)	6.6 (3.5)	15.0 (3.0)	0.95 (0.31)	1.25 (0.45)	12.8 (3.3)	25.3 (7.6)	60.8 (15.3)

984

985

986

987

988

989

990

991

Extended Effects of a Wearable Sensory Prosthesis

992 **Table 2.** Baseline characteristics for participants reaching the 26 Week assessment (n=44). Participants who reported
 993 having fallen in the past six months (Pre-F) and those who did not (Pre-NF) are reported separately. Values represent
 994 Mean (Standard Deviation). Column p-level shows significance level for comparison between the Pre-F and Pre-NF
 995 groups. In bold if p<0.05.

996 *Fall-risk factors assessed in the current study included, recent history of falls (Tinetti and Kumar 2010), PN diagnosis
 997 (Richardson and Hurvitz 1995), FGA score<23 (Wrisley and Kumar 2010), TUG >12 s (CDC 2017), 4-Stage Balance
 998 Test<30s (CDC 2017), Gait Speed <0.7m/s (Studenski, Perera et al. 2003, Montero-Odasso, Schapira et al. 2005), and
 999 ABC score <67% (Lajoie and Gallagher 2004).

1000
1001

Baseline Assessment	All n=44	Pre-F n=25	Pre-NF n=19	p-level
Gender Female (n)	8 of 44 (18%)	8 of 25 (32%)	0 of 19 (0%)	<0.01
Use of Assistive Device (n)	25 of 44 (57%)	18 of 25 (72%)	7 of 19 (37%)	0.02
Gait Speed Self-selected <0.7m/s (n)	8 of 44 (18%)	7 of 25 (28%)	1 of 19 (5%)	0.052
Timed Up and Go >12s (n)	21 of 44 (48%)	16 of 25 (64%)	5 of 19 (26%)	0.013
4-Stage Balance Test <30s (n)	28 of 44 (64%)	18 of 25 (72%)	10 of 19 (53%)	0.19
ABC Score <67% (n)	24 of 44 (54%)	17 of 25 (68%)	7 of 19 (37%)	0.04
Fallen in Last 6 Months (n)	25 of 44 (57%)	25 of 25 (100%)	0 of 19 (0%)	n/a
Fallen in Last 12 Months (n)	31 of 44 (70%)	25 of 25 (100%)	6 of 19 (32%)	<0.0001
Number of Falls 6 Months	53	53	0	n/a
Number of Falls 12 Months	106	97 of 106 (92%)	9 of 106 (8%)	<0.0001
	Mean (SD) n=44	Mean (SD) n=25	Mean (SD) n=19	p-level
Age (yrs)	73.5 (7.8)	73.1 (7.9)	73.9 (7.8)	0.72
Height (m)	1.76 (0.09)	1.76 (0.12)	1.76 (0.05)	0.96
Weight (kg)	90.7 (15.3)	89.7 (17.3)	92.0 (12.5)	0.63
BMI (kg/m ²)	29.4 (4.6)	29.0 (5.2)	29.8 (3.8)	0.59
FGA Score	15.3 (3.7)	13.9 (3.4)	17.3 (3.3)	<0.002
Gait Speed, Self-selected (m/s)	0.89 (0.23)	0.83 (0.23)	0.97 (0.21)	<0.05
Gait Speed, Fast (m/s)	1.29 (0.36)	1.13 (0.29)	1.50 (0.35)	<0.0005
TUG (s)	12.9 (4.0)	14.1 (4.4)	11.4 (2.8)	<0.026
4-Stage Balance Test (s)	25.9 (7.2)	24.5 (6.3)	27.8 (8.1)	0.14
Fall-Risk Factors* (n of 7)	3.4 (1.5)	4.3 (0.9)	2.2 (1.1)	<0.0001
# Chronic Conditions	8.3 (3.3)	8.8 (3.3)	7.5 (3.3)	0.21
ABC Score (%)	62.9 (16.2)	57.8 (14.0)	69.6 (16.8)	<0.02
VADL Mean Score	3.7 (1.10)	4.1 (1.0)	3.1 (0.8)	<0.001
VAS Pain Score (0-10)	2.9 (2.1)	3.0 (2.1)	2.8 (2.2)	0.89
PHQ-9	4.7 (4.0)	5.7 (4.5)	3.3 (2.9)	0.052
Pain Interference PROMIS® 6b	50.9 (8.1)	52.7 (7.7)	48.5 (8.1)	0.09
Satisfaction Social Roles PROMIS® 8a	49.8 (7.0)	49.8 (6.7)	49.9 (7.5)	0.96
Ability to Participate PROMIS® 8a	49.9 (7.4)	48.4 (6.7)	51.8 (8.0)	0.13

1002
1003
1004
1005
1006
1007

Extended Effects of a Wearable Sensory Prosthesis

1008 **Table 3.** Clinical outcomes and Rydel-Seiffer vibration sensation screening for the 30 individuals who were able to
 1009 complete all in-person assessments at baseline and after 26 weeks as well as the subgroups of Pre-Fallers and Pre-
 1010 NonFallers. Statistical significance is indicated in **bold**. Bonferroni’s adjustment of significance levels for correlated
 1011 measures was applied (Uitenbroek 1997).

1012 Values in (italics) indicate Pearson’s correlation coefficient followed by the adjusted significance level required for an
 1013 overall significance of 0.05 as marked with *.

1014 Cohen’s d_{rm} indicates effect size for change between baseline and the primary endpoint 10 weeks where 0.2 is represents
 1015 a small effect, 0.5 a medium effect, and 0.8 a large effect. Values in parenthesis show 95% confidence interval.
 1016 “estimate the effect size for single-group pretest-posttest designs” (Morris and DeShon 2002)
 1017

All	Baseline Mean (SD) n=30	26-week Mean (SD) n=30	p-level	Cohen’s d_{rm} (95% CI’s)
FGA Score	15.0 (3.9)	19.2 (4.1) (0.69) 0.036*	<0.00001	1.38 (0.82-1.94)
Gait Speed Self-selected (m/s)	0.89 (0.26)	0.97 (0.28) (0.80) 0.040*	0.02	0.49 (-0.03-1.0)
Gait Speed Fast (m/s)	1.30 (0.41)	1.37 (0.42)	0.07	n/a
TUG (s)	13.2 (4.6)	12.3 (3.4)	0.20	n/a
4-Stage Balance Test (s)	25.6 (7.2)	28.4 (5.7) (0.65) 0.034*	<0.01	0.47 (-0.05-0.98)
R/L 1st MTP Joint	2.8 (2.5)	2.2 (2.4)	0.07	n/a
R/L Lateral Malleolus	3.8 (2.2)	3.2 (2.1) (0.60) 0.032*	0.032	0.32 (-0.19-0.83)
R/L Patella	4.0 (2.2)	4.0 (1.8)	0.91	n/a
Pre-Fallers	Baseline Mean (SD) n=18	26-week Mean (SD) n=18	p-level	Cohen’s d_{rm} (95% CI’s)
FGA Score	13.7 (3.7)	18.1 (3.6) (0.72) 0.037*	<0.0001	1.58 (0.83-2.33)
Gait Speed Self-selected (m/s)	0.82 (0.25)	0.90 (0.29)	0.12	n/a
Gait Speed Fast (m/s)	1.13 (0.33)	1.23 (0.37)	0.07	n/a
TUG (s)	14.5 (5.0)	13.0 (3.9)	0.14	n/a
4-Stage Balance Test (s)	23.5 (6.5)	27.7 (5.4) (0.69) 0.037*	<0.02	0.82 (0.14-1.50)
R/L 1st MTP Joint	2.9 (2.4)	1.8 (2.0) (0.55) 0.03*	0.005	0.58 (-0.09-1.24)
R/L Lateral Malleolus	3.75 (2.1)	3.25 (1.9)	0.07	n/a
R/L Patella	4.2 (2.0)	4.0 (1.9)	0.64	n/a
Pre-NonFallers	Baseline Mean (SD) n=12	26-week Mean (SD) n=12	p-level	Cohen’s d_{rm} (95% CI’s)
FGA Score	17.0 (3.3)	20.8 (4.3) (0.56) 0.031*	0.004	1.23 (0.36-2.10)
Gait Speed Self-selected (m/s)	1.00(0.25)	1.08 (0.25)	0.06	n/a
Gait Speed Fast (m/s)	1.56 (0.40)	1.59 (0.42)	0.63	n/a
TUG (s)	11.1 (3.1)	11.3 (2.5)	0.78	n/a
4-Stage Balance Test (s)	28.7 (7.4)	29.5 (6.1)	0.65	n/a
R/L 1st MTP Joint	2.5 (2.8)	2.7 (2.8)	0.76	n/a
R/L Lateral Malleolus	3.7 (2.5)	3.1 (2.4)	0.21	n/a
R/L Patella	3.7 (2.5)	4.0 (1.7)	0.68	n/a

1018

Extended Effects of a Wearable Sensory Prosthesis

1019 **Table 4.** Results from self-reported outcomes for the 44 individuals who completed all assessments. Data are shown
 1020 separately for the group as a whole and for Pre-Fallers (having reported fallen in the prior 6 months) and Pre-NonFallers
 1021 (no falls reported in the prior 6 months).
 1022

	Baseline Mean (SD) n=44	26-week Mean (SD) n=44	p-level
ABC-Score (%)	62.9 (16.2)	65.1 (14.8)	0.39
VADL Mean Score	3.70 (1.06)	3.46 (1.10)	0.08
VAS Score (0-10)	2.9 (2.1)	2.8 (2.2)	0.66
PHQ-9	4.7 (4.0)	3.9 (4.2)	0.14
Pain Interference PROMIS® 6b	50.9 (8.1)	51.1 (8.3)	0.88
Satisfaction Social Roles PROMIS® 8a	49.8 (7.0)	51.9 (8.3)	0.075
Ability to Participate PROMIS® 8a	49.9 (7.4)	52.6 (8.6)	<0.05
Pre-Fallers (n=25)	Baseline Mean (SD)	26-week Mean (SD)	
ABC-Score (%)	57.8 (13.9)	59.1 (14.4)	0.73
VADL Mean Score	4.14 (1.00)	3.95 (0.79)	0.32
VAS Score (0-10)	3.0 (2.1)	3.1 (1.9)	0.76
PHQ-9	5.7 (4.7)	5.1 (4.5)	0.22
Pain Interference PROMIS® 6b	52.7 (8.0)	52.9 (7.3)	0.86
Satisfaction Social Roles PROMIS® 8a	49.8 (6.7)	49.2 (6.8)	0.69
Ability to Participate PROMIS® 8a	48.4 (7.1)	50.0 (7.1)	0.12
Pre-NonFallers (n=19)	Baseline Mean (SD)	26-week Mean (SD)	
ABC-Score (%)	69.6 (17.1)	73.0 (12.0)	0.34
VADL Mean Score	3.11 (0.86)	2.81 (1.00)	0.14
VAS Score (0-10)	2.8 (2.2)	2.4 (2.4)	0.35
PHQ-9	3.3 (2.9)	2.4 (3.5)	0.35
Pain Interference PROMIS® 6b	48.5 (8.1)	48.6 (9.2)	0.96
Satisfaction Social Roles PROMIS® 8a	49.9 (7.7)	55.5 (8.9)	0.006
Ability to Participate PROMIS® 8a	51.8 (7.5)	55.0 (10.0)	0.18

1023
 1024
 1025


Extended Effects of a Wearable Sensory Prosthesis

1026 **Table 5.** Parameters related to falls and fall risk assessed at baseline and at 26 weeks. All 44 individuals were asked to
 1027 report their falls throughout the 26-week period. Data for Pre-Fallers and Pre-NonFallers are presented separately. Fall
 1028 rates are reported in number of falls per 1000 patient days. Fall rates were not normally distributed (Shapiro–Wilk W-stat
 1029 =0.82).
 1030 *Wilcoxon Signed Rank test.
 1031

All (n=44)	Baseline (SD)	26 Weeks (SD)	p-level
#Falls (pre-6 mo & in study, n=44)	53	39	n/a
Fall Rate Mean (#/1000 patient days, pre-6mo & in study, n=44)	6.7 (7.7)	4.8 (7.7)	n/a
Fall Rate Median	5.6	0	0.044*
#Fallers (pre-6mo & at 6mo in study, n=44)	25	20	0.28
Falls no treatment sought	n/a	31	n/a
Falls treatment sought + severe injury	n/a	4+4	n/a
Pre-Fallers (n=25)			
#Falls (pre-6 mo & in study, n=25)	53	31	n/a
Fall Rate Mean (#/1000 patient days, pre-6mo & in study, n=25)	11.8 (6.7)	6.7 (9.5)	n/a
Fall Rate Median	11.1	5.0	0.0043*
#Fallers (pre-6mo & at 6mo in study, n=25)	25	13	<0.0001
Falls no treatment sought	n/a	25	n/a
Falls treatment sought + severe injury	n/a	3+3	n/a
Pre-NonFallers (n=19)			
#Falls (pre-6 mo & in study, n=19)	0	8	n/a
Fall Rate Mean (#/1000 patient days, pre-6mo & in study, n=19)	0 (0)	2.3 (3.3)	n/a
Fall Rate Median	0	0	0.023*
#Fallers (pre-6mo & at 6mo in study, n=19)	0	7	<0.0001
Falls no treatment sought	n/a	6	n/a
Falls treatment sought + severe injury	n/a	1+1	n/a

1032
 1033
 1034
 1035
 1036
 1037
 1038
 1039


Extended Effects of a Wearable Sensory Prosthesis



1040
1041
1042 *Figure 1. (Left) The two components of the Walkasins device, the pressure sensitive flexible foot pad that is placed in the*
1043 *shoe and connects to the leg unit that contains a rechargeable battery, a microprocessor, supporting electronics, and four*
1044 *tactile stimulators. The embedded software algorithm evaluates pressure data and activates tactile stimulators at relevant*
1045 *times during standing and walking to signal balance-related information to the afferent nervous system. (Right) A*
1046 *Walkasins user wearing the device in the process of turning it on. The Walkasins system is worn bilaterally (unilateral*
1047 *components depicted).*

1048
1049
1050
1051
1052
1053
1054
1055

Extended Effects of a Wearable Sensory Prosthesis



1056

1057

1058


1059

1060

Figure 2. Flowchart of the walk2Wellness trial. Data for the primary endpoint at 10 weeks, shown to the right for reference, were published earlier (Oddsson, Bisson et al. 2020). Due to COVID-19 site lockdowns, in-person outcomes could be assessed from 30 of the 44 participants. Self-reported outcomes and fall events were assessed from all 44 participants who reached the 26-week follow-up visit.

Extended Effects of a Wearable Sensory Prosthesis

1061
1062




1063

1064
1065
1066
1067
1068
1069
1070
1071
1072

Figure 3. Comparing FGA scores at baseline (horizontal axes) with assessments after 2, 6, 10, and 26 weeks (vertical axes) of device use. Open symbols represent pre-study non-fallers and filled ones are pre-study fallers. Dashed lines show regression line for the whole group. Forty-four participants completed in clinic outcomes testing up to 10 weeks (primary endpoint), and 30 participants completed the 26-week assessment in person. Scores above line of equality indicate improvements and below a decrement in FGA score compared to baseline scores. Notice that regression line slopes are less than 1 indicating slightly larger improvements in FGA score for those with lower baseline scores. Overall, improvements observed after 2 weeks of use appeared sustained throughout the 26 weeks of use.

1073
1074
1075
1076
1077
1078
1079
1080
1081
1082

Extended Effects of a Wearable Sensory Prosthesis



1083

1084

1085

1086


1087 *Figure 4. Averages of clinical outcomes across the in-person assessments at baseline (0), 2, 6, 10, and 26 weeks for the*
 1088 *30 participants (blue lines and symbols) who were able to be tested in clinic after 26 weeks of device use. Grey symbols*
 1089 *and lines represent the pre-study non-fallers (n=12 of 30,) and orange lines and symbols represent pre-study fallers*
 1090 *(n=18 of 30). Notice that most improvements appeared to peak after 6-10 weeks of device use, followed by a leveling off*
 1091 *until 26 weeks.*

1092

1093

Extended Effects of a Wearable Sensory Prosthesis

1094
1095
1096
1097




1098
1099 *Figure 5. Illustration of changes in ABC/FGA ratio (left axis, solid lines), an indication of self-perceived balance*
1100 *confidence in relation to externally observed gait function performance, for participants with baseline ABC scores >67%*
1101 *(high balance-confidence, orange triangles) and those with ABC scores \leq 67% (low balance-confidence, blue circles).*
1102 *The associated changes over time in FGA scores for the same two groups are also shown (right axis, dashed lines).*
1103 *Notice that both groups had similar FGA scores at baseline, which led to a dramatic difference in the ABC/FGA ratio at*
1104 *baseline. Over time, the ratio for the high balance-confidence participants gradually decreased and aligned with the low*
1105 *balance-confidence group at \sim 3.5, mainly due to an increased FGA score and a maintained ABC score. The low balance-*
1106 *confidence group maintained an ABC/FGA ratio \sim 3.5 throughout the 26 weeks associated with a proportional increase in*
1107 *ABC and FGA scores. Interestingly, the high balance-confidence group showed a higher increase in FGA score than the*
1108 *low balance-confidence group.*

1109
1110
1111
1112
1113
1114

Extended Effects of a Wearable Sensory Prosthesis

1115



1116

1117

1118

1119

1120

1121

1122

1123

1124

Figure 6. Accumulated number of falls reported six months pre-study (blue trace and blue dotted linear regression line) and falls documented in-study (orange trace and orange dotted regression line). The 53 falls reported for the prior six months would correspond to 0.29 falls/day (53/180~0.29), which represents the slope of the regression line (blue trace). For illustration purposes, the 53 pre-study falls were randomly distributed across the six months since their exact time occurrence was unknown. In-study falls are shown as they occurred and were reported by participants throughout the 26 weeks. Notice how the rate of in-study falls appear to begin deviating from pre-study fall rate (slope of dotted blue line) after approximately 20 days of device use.

1125

1126

1127

1128

1129

1130